~~Jan~~ please.

116405

Access DB# _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: S. Kumar Examiner #: 69594 Date: 3/9/04
Art Unit: 1621 Phone Number 30571-272-0690 Serial Number: 09/200,498
Mail Box and Bldg/Room Location: REM 5D60 3C18 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Novel substituted cyclic compounds, preparation method and....

Inventors (please provide full names): Daniel Lesieur et al

Earliest Priority Filing Date: 5/12/1998

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

R - A - R'

A is  or



or

X is O, S, N or CH
Y is N, CH
Z is N, CH
B is benzene, pyridine

R is S - R'' , NR'R''
(O)

R' is G - R²

R² is -N - C - R etc.
O

See claims.

Species: N-{2-[7-(Methylthio)-1-naphthyl]ethyl} acetamide.

****

STAFF USE ONLY	**Type of Search**		**Vendors and cost where applicable**	
Searcher:	NA Sequence (#)		STN	✓
Searcher Phone #: 72503	AA Sequence (#)		Dialog	
Searcher Location:	Structure (#)	✓	Questel/Orbit	
Date Searcher Picked Up: 3/11/04	Bibliographic		Dr.Link	
Date Completed:	Litigation		Lexis/Nexis	
Searcher Prep & Review Time:	Fulltext		Sequence Systems	
Clerical Prep Time: 60	Patent Family		WWW/Internet	
Online Time: ~ 45	Other		Other (specify)	

PTO-1590 (8-01)

STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 116405

TO: Shailendra Kumar **Location: 5d61 / 5c18** **Thursday, March 11, 2004** **Art Unit: 1621** **Phone: 272-0640** **Serial Number: 09 / 700098**	**From: Jan Delaval** **Location: Biotech-Chem Library** **Rem 1A51** **Phone: 272-2504** **jan.delaval@uspto.gov**

Search Notes

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 12:23:46 ON 11 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   10 MAR 2004  HIGHEST RN 661450-61-9
DICTIONARY FILE UPDATES:  10 MAR 2004  HIGHEST RN 661450-61-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d l22 ide can tot

L22  ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   250161-79-6  REGISTRY
CN   Acetamide, N-[2-[1,2,3,4-tetrahydro-7-(methylthio)-1-naphthalenyl]ethyl]-
     (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   N-[2-[7-(Methylthio)-1,2,3,4-tetrahydro-1-naphthalenyl]ethyl]acetamide
FS   3D CONCORD
MF   C15 H21 N O S
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE   1:  131:336827

L22  ANSWER 2 OF 2  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   250161-68-3  REGISTRY
CN   Acetamide, N-[2-[7-(methylthio)-1-naphthalenyl]ethyl]- (9CI)  (CA INDEX
     NAME)
OTHER NAMES:
CN   N-[2-[7-(Methylthio)-1-naphthyl]ethyl]acetamide
FS   3D CONCORD
MF   C15 H17 N O S
SR   CA
```

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:336827

=> d his l22-

(FILE 'REGISTRY' ENTERED AT 12:20:46 ON 11 MAR 2004)
L22 2 S L20,L21
SEL RN
L23 0 S E201-202/CRN

FILE 'HCAOLD' ENTERED AT 12:23:10 ON 11 MAR 2004
L24 0 S L22

FILE 'HCAPLUS' ENTERED AT 12:23:13 ON 11 MAR 2004
L25 1 S L22
L26 1 S L25 AND L1-L14

FILE 'USPATFULL, USPAT2' ENTERED AT 12:23:36 ON 11 MAR 2004
L27 3 S L22

FILE 'REGISTRY' ENTERED AT 12:23:46 ON 11 MAR 2004

=> fil uspatall
FILE 'USPATFULL' ENTERED AT 12:23:55 ON 11 MAR 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:23:55 ON 11 MAR 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> d l27 bib abs hitstr tot

L27 ANSWER 1 OF 3 USPATFULL on STN
AN 2004:2468 USPATFULL
TI Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them
IN Lesieur, Daniel, Gondecourt, FRANCE
Klupsch, Frederique, Hulluch, FRANCE
Guillaumet, Gerald, Saint Jean Le Blanc, FRANCE
Viaud, Marie-Claude, Tours, FRANCE
Langlois, Michel, Sceaux, FRANCE
Bennejean, Caroline, Charenton Le Pont, FRANCE
Renard, Pierre, Le Chesnay, FRANCE
Delagrange, Philippe, Issy Les Moulineaux, FRANCE
PI US 2004002491 A1 20040101
AI US 2003-462331 A1 20030616 (10)
RLI Division of Ser. No. US 2000-700056, filed on 10 Nov 2000, GRANTED, Pat.

No. US 6605632 A 371 of International Ser. No. WO 1999-FR1101, filed on 10 May 1999, UNKNOWN
PRAI FR 1998-5957 19980512
DT Utility
FS APPLICATION
LREP THE FIRM OF HUESCHEN AND SAGE, 500 COLUMBIA PLAZA, 350 EAST MICHIGAN AVENUE, KALAMAZOO, MI, 49007
CLMN Number of Claims: 68
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns compounds of formula (1): R-A-R' wherein: A is as defined in the description; R represent a group (V), (VI), (VII), or (VIII), where E, Q, R.sup.1, R.sup.2, R.sup.3, v and R.sup.4 are as defined in the description; R' represents a --(CH.sub.2).sub.t--R.sup.5 group wherein t and R.sup.5 are as defined in the description, and medicaments containing the same. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **250161-68-3P**, N-[2-[7-(Methylthio)-1-naphthyl]ethyl]acetamide
250161-79-6P, N-[2-[7-(Methylthio)-1,2,3,4-tetrahydro-1-naphthalenyl]ethyl]acetamide
(target compound; preparation of bicyclic aromatic and heteroarom. compds. as
melatonin receptor ligands)
RN 250161-68-3 USPATFULL
CN Acetamide, N-[2-[7-(methylthio)-1-naphthalenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 250161-79-6 USPATFULL
CN Acetamide, N-[2-[1,2,3,4-tetrahydro-7-(methylthio)-1-naphthalenyl]ethyl]- (9CI) (CA INDEX NAME)



L27 ANSWER 2 OF 3 USPATFULL on STN
AN 2004:2467 USPATFULL
TI Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them
IN Lesieur, Daniel, Gondecourt, FRANCE
Klupsch, Frederique, Hulluch, FRANCE
Guillaumet, Gerald, Saint Jean Le Blanc, FRANCE
Viaud, Marie-Claude, Tours, FRANCE
Langlois, Michel, Sceaux, FRANCE
Bennejean, Caroline, Charenton Le Pont, FRANCE

Renard, Pierre, Le Chesnay, FRANCE
Delagrange, Philippe, Issy Les Moulineaux, FRANCE
PI US 2004002490 A1 20040101
AI US 2003-462326 A1 20030616 (10)
RLI Division of Ser. No. US 2000-700056, filed on 10 Nov 2000, GRANTED, Pat. No. US 6605632 A 371 of International Ser. No. WO 1999-FR1101, filed on 10 May 1999, UNKNOWN
PRAI FR 1998-5957 19980512
DT Utility
FS APPLICATION
LREP THE FIRM OF HUESCHEN AND SAGE, 500 COLUMBIA PLAZA, 350 EAST MICHIGAN AVENUE, KALAMAZOO, MI, 49007
CLMN Number of Claims: 68
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3303
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns compounds of formula (I): R-A-R' wherein: A is as defined in the description; R represent a group (V), (VI), (VII), or (VIII), where E, Q, R.sup.1, R.sup.2, R.sup.3, v and R.sup.4 are as defined in the description; R' represents a --(CH.sub.2).sub.t--R.sup.5 group wherein t and R.sup.5 are as defined in the description, and medicaments containing the same. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **250161-68-3P**, N-[2-[7-(Methylthio)-1-naphthyl]ethyl]acetamide
250161-79-6P, N-[2-[7-(Methylthio)-1,2,3,4-tetrahydro-1-naphthalenyl]ethyl]acetamide
(target compound; preparation of bicyclic aromatic and heteroarom. compds. as
melatonin receptor ligands)
RN 250161-68-3 USPATFULL
CN Acetamide, N-[2-[7-(methylthio)-1-naphthalenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 250161-79-6 USPATFULL
CN Acetamide, N-[2-[1,2,3,4-tetrahydro-7-(methylthio)-1-naphthalenyl]ethyl]- (9CI) (CA INDEX NAME)



L27 ANSWER 3 OF 3 USPATFULL on STN
AN 2003:216188 USPATFULL
TI Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them
IN Lesieur, Daniel, Gondecourt, FRANCE

Klupsch, Frederique, Hulluch, FRANCE
Guillaumet, Gerald, Saint Jean le Blanc, FRANCE
Viaud, Marie-Claude, Tours, FRANCE
Langlois, Michel, Sceaux, FRANCE
Bennejean, Caroline, Charenton le Pont, FRANCE
Renard, Pierre, Le Chesnay, FRANCE
Delagrange, Philippe, Issy les Moulineaux, FRANCE
PA Les Laboratoires Servier, Neuilly-sur-Seine, FRANCE (non-U.S. corporation)
PI US 6605632 B1 20030812
WO 9958496 19991118
AI US 2000-700056 20001110 (9)
WO 1999-FR1101 19990510
PRAI FR 1998-5957 19980512
DT Utility
FS GRANTED
EXNAM Primary Examiner: Raymond, Richard L.; Assistant Examiner: Balasubrasubramanian, Venkataraman
LREP The Firm of Hueschen and Sage
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2933
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns compounds of formula (I): R--A--R' wherein: A is as defined in the description; R represents a group (V), (VI), (VII) or (VIII), where E, Q, R.sup.1, R.sup.2, R.sup.3, v and R.sup.4 are as defined in the description; R' represents a --(CH.sub.2).sub.t--R.sup.5 group wherein t and R.sup.5 are as defined in the description ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **250161-68-3P**, N-[2-[7-(Methylthio)-1-naphthyl]ethyl]acetamide
250161-79-6P, N-[2-[7-(Methylthio)-1,2,3,4-tetrahydro-1-naphthalenyl]ethyl]acetamide
(target compound; preparation of bicyclic aromatic and heteroarom. compds. as
melatonin receptor ligands)
RN 250161-68-3 USPATFULL
CN Acetamide, N-[2-[7-(methylthio)-1-naphthalenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 250161-79-6 USPATFULL
CN Acetamide, N-[2-[1,2,3,4-tetrahydro-7-(methylthio)-1-naphthalenyl]ethyl]- (9CI) (CA INDEX NAME)



```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 12:24:06 ON 11 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 11 Mar 2004  VOL 140 ISS 11
FILE LAST UPDATED: 10 Mar 2004  (20040310/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=> d l26 all hitstr

L26  ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2004 ACS on STN
AN   1999:736646  HCAPLUS
DN   131:336827
ED   Entered STN:  19 Nov 1999
TI   Novel substituted cyclic compounds, particularly N-[2-(1-
     naphthyl)ethyl]acetamides and analogs with melatonin receptor activity,
     preparation method, and pharmaceutical compositions containing them
IN   Lesieur, Daniel; Klupsch, Frederique; Guillaumet,
     Gerald; Viaud, Marie-Claude; Langlois, Michel;
     Bennejean, Caroline; Renard, Pierre; Delagrange,
     Philippe
PA   Adir Et Compagnie, Fr.
SO   PCT Int. Appl., 167 pp.
     CODEN: PIXXD2
DT   Patent
LA   French
IC   ICM  C07C233-36
     ICS  C07C233-40; C07C317-32; C07C323-40; C07C323-41; C07C323-44;
          C07D209-60; C07D221-10; C07D295-12; C07D307-81; C07D333-58;
          C07D335-08; C07D407-12; C07D471-04; C07D495-04; A61K031-165
CC   25-24 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
     Section cross-reference(s): 1
FAN.CNT 2
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 9958495         A1   19991118       WO 1999-FR1100   19990510 <--
         W:  AU, BR, CA, CN, HU, JP, NO, NZ, PL, US, ZA
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE
     FR 2778662          A1   19991119       FR 1998-5957     19980512 <--
     FR 2778662          B1   20000616
     CA 2331870          AA   19991118       CA 1999-2331870  19990510 <--
     AU 9936103          A1   19991129       AU 1999-36103    19990510 <--
     AU 748567           B2   20020606
     EP 1077927          A1   20010228       EP 1999-918036   19990510 <--
```

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI

	BR 9911771	A	20011002	BR 1999-11771	19990510	<--
	JP 2002514619	T2	20020521	JP 2000-548299	19990510	<--
	NZ 507691	A	20020531	NZ 1999-507691	19990510	<--
	ZA 2000006529	A	20010522	ZA 2000-6529	20001110	<--
	ZA 2000006528	A	20011114	ZA 2000-6528	20001110	<--
	NO 2000005714	A	20001113	NO 2000-5714	20001113	<--
PRAI	FR 1998-5957	A	19980512	<--		
	WO 1999-FR1100	W	19990510	<--		

OS MARPAT 131:336827

GI



II

AB The invention concerns compds. of formula R-A-R' [I; wherein: A = various bi- and tricyclic carbo- and heterocyclic systems; R = SH and various derivs. such as thioethers, sulfoxides, and sulfones, (un)substituted amino, or may form ring with A; R' = (CH2)nR2 where n = 0-4 and R2 = various amide-containing groups] and their stereoisomers and salts. The compds. are ligands of melatonin receptors, and are useful for preparing medicines for treating a variety of melatonin-related conditions, such as seasonal depression, anxiety, sleep and eating disorders, etc. For instance, title compound II was prepared in 7 steps: (1) acylation of thioanisole with succinic anhydride to give 4-[4-(methylthio)phenyl]-4-oxobutanoic acid; (2) reduction of oxo with Et3SiH; (3) cyclization to form a 1-naphthalenone; (4) Wittig reaction with di-Et cyanomethylphosphonate; (5) dehydrogenation with sulfur at 230°; (6) reduction of the nitrile with BH3.THF; and (7) N-acetylation of the resulting amine with AcCl. Compds. I showed little or no oral toxicity in mice, and bound strongly to mt1 and MT2 receptors in vitro, with IC50 values ≤ 10 μM. The compds. also showed circadian rhythm, anxiolytic, and vasoconstrictor/vasodilator activities in rats or in vitro.

ST naphthylethylacetamide prepn melatonin receptor ligand; methylthionaphthylethylacetamide prepn anxiolytic vasodilator

IT Rhythm, biological
(circadian; preparation of bicyclic aromatic and heteroarom. compds. as melatonin receptor ligands)

IT Appetite
Sleep
(disorder, treatment; preparation of bicyclic aromatic and heteroarom. compds. as melatonin receptor ligands)

IT Antidepressants
Antiobesity agents
Anxiolytics
Cardiovascular agents
Vasoconstrictors
Vasodilators
(preparation of bicyclic aromatic and heteroarom. compds. as melatonin receptor ligands)

IT Melatonin receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(preparation of bicyclic aromatic and heteroarom. compds. as melatonin receptor ligands)

IT Insomnia
(treatment; preparation of bicyclic aromatic and heteroarom. compds. as melatonin receptor ligands)

IT 366-77-8P, 4-(4-Fluorophenyl)-4-oxobutanoic acid 589-06-0P, 4-(4-Fluorophenyl)butanoic acid 2840-44-0P, 7-Fluoro-3,4-dihydro-1(2H)-naphthalenone 7028-67-3P, 4-[4-(Methylthio)phenyl]-4-oxobutanoic acid 23962-24-5P, N-[2-(5-Chlorobenzo[b]thiophen-3-yl)ethyl]acetamide 51828-63-8P, 5-Chloro-3-methyl-2-phenyl-1-benzothiophene 51828-64-9P, 3-(Bromomethyl)-5-chloro-2-phenyl-1-benzothiophene 65712-06-3P, 2-(5-Chloro-2-phenyl-1-benzothiophen-3-yl)-1-ethanamine hydrochloride 65712-14-3P, 2-(5-Chloro-2-phenyl-1-benzothiophen-3-yl)acetonitrile 116174-33-5P, 4-[4-(Methylthio)phenyl]butanoic acid 250162-30-2P, 2-[7-(Methylthio)-1-naphthyl]-1-ethylamine hydrochloride 250162-31-3P, 2-[7-(Methylthio)-1,2,3,4-tetrahydro-1-naphthalenylidene]acetonitrile 250162-32-4P, N-[2-(5-Chloro-2-phenylbenzo[b]thiophen-3-yl)ethyl]acetamide 250162-33-5P, N-[2-(5-Chlorobenzo[b]thiophen-3-yl)ethyl]acrylamide 250162-34-6P, N-[2-(5-Chlorobenzo[b]thiophen-3-yl)ethyl]-2,2,2-trifluoroacetamide 250162-35-7P, N-[2-(5-Chlorobenzo[b]thiophen-3-yl)ethyl]-1-cyclopropanecarboxamide 250162-37-9P, N-[2-(5-Bromobenzo[b]thiophen-3-yl)ethyl]acetamide 250162-38-0P, N-[2-(5-Bromobenzo[b]thiophen-3-yl)ethyl]-2,2,2-trifluoroacetamide 250162-39-1P, N-[2-(5-Bromobenzo[b]thiophen-3-yl)ethyl]butanamide 250162-40-4P, N-[2-(5-Bromobenzo[b]thiophen-3-yl)ethyl]-N'-methylurea 250162-41-5P, N-[2-(5-Bromobenzo[b]thiophen-3-yl)ethyl]benzamide 250162-42-6P, N-[2-(5-Bromobenzo[b]thiophen-3-yl)ethyl]-2-(3,4-dichlorophenyl)acetamide 250162-43-7P, N-[2-(5-Bromobenzo[b]thiophen-3-yl)ethyl]-3-butenamide 250162-44-8P, N-[2-(7-Fluoro-1,2,3,4-tetrahydro-1-naphthalenyl)ethyl]acetamide 250162-46-0P, 2-(7-Fluoro-1,2,3,4-tetrahydro-1-naphthalenyl)-1-ethylamine hydrochloride 250162-47-1P, N-[2-(5-Bromo-1-benzothiophen-3-yl)ethyl]-2-phenylacetamide 250162-48-2P, N-[2-(5-Bromo-1-benzothiophen-3-yl)ethyl]-3,4-dichlorobenzamide 250162-49-3P, N-[2-(5-Bromo-1-benzothiophen-3-yl)ethyl]-2-furamide 250162-50-6P, N-[2-(5-Chloro-1-benzothiophen-3-yl)ethyl]-2-butynamide 250162-51-7P, 4-Chloro-N-[2-(5-chloro-1-benzothiophen-3-yl)ethyl]butanamide 250162-52-8P, N-[2-(5-Chloro-1-benzothiophen-3-yl)ethyl]-2-furamide 250162-53-9P, N-[2-(5-Bromo-2-phenyl-1-benzothiophen-3-yl)ethyl]acetamide 250162-54-0P, N-[2-(5-Chloro-1-benzothiophen-3-yl)ethyl]-3-phenyl-2-propenamide 250162-55-1P, N-[2-(5-Bromo-1-benzothiophen-3-yl)ethyl]-3-phenyl-2-propenamide 250162-56-2P, N-[2-(5-Chloro-1-benzothiophen-3-yl)ethyl]-4-phenyl-3-butenamide 250162-57-3P, N-[2-(5-Bromo-1-benzothiophen-3-yl)ethyl]-4-phenyl-3-butenamide 250162-58-4P, N-[2-(5-Chloro-1-benzothiophen-3-yl)ethyl]-3-butenamide 250162-59-5P, N-[2-(5-Bromo-2-phenyl-1-benzothiophen-3-yl)ethyl]-3-butenamide 251934-90-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of bicyclic aromatic and heteroarom. compds. as melatonin receptor ligands)

IT 73-31-4, Melatonin
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(preparation of bicyclic aromatic and heteroarom. compds. as melatonin receptor ligands)

IT 75-08-1, Ethanethiol 98-88-4, Benzoyl chloride 100-53-8, Benzyl thiol 100-68-5, Thioanisole 107-03-9, 1-Propanethiol 108-30-5, reactions

141-75-3, Butanoyl chloride 462-06-6, Fluorobenzene 624-83-9, Methyl isocyanate 2537-48-6, Diethyl (cyanomethyl)phosphonate 4023-34-1, Cyclopropanecarboxylic acid chloride 51828-62-7, 1-[(4-Chlorophenyl)thio]-1-phenylacetone 152302-45-9, N-[2-(7-Hydroxy-1-naphthyl)ethyl]acetamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of bicyclic aromatic and heteroarom. compds. as
melatonin receptor ligands)

IT 250133-76-7P, N-[2-[7-(Benzylthio)-1-naphthyl]ethyl]acetamide
250161-68-3P, N-[2-[7-(Methylthio)-1-naphthyl]ethyl]acetamide
250161-69-4P, N-[2-[7-(Methylthio)-1-naphthyl]ethyl]butanamide
250161-70-7P, N-[2-[7-(Methylthio)-1-naphthyl]ethyl]-1-cyclopropanecarboxamide 250161-71-8P, N-[2-[7-(Methylthio)-1-naphthyl]ethyl]-2,2,2-trifluoroacetamide 250161-72-9P, N-Methyl-N'-[2-[7-(methylthio)-1-naphthyl]ethyl]urea 250161-73-0P, N-[2-[3-Benzoyl-7-(methylthio)-1-naphthyl]ethyl]acetamide 250161-74-1P, N-[2-[3-Benzyl-7-(methylthio)-1-naphthyl]ethyl]acetamide 250161-75-2P, N-[2-[7-(Ethylthio)-1-naphthyl]ethyl]acetamide 250161-76-3P, N-[2-[7-(Propylthio)-1-naphthyl]ethyl]acetamide 250161-77-4P, N-[2-[7-(Methylsulfinyl)-1-naphthyl]ethyl]acetamide 250161-78-5P, N-[2-[7-(Methylsulfonyl)-1-naphthyl]ethyl]acetamide **250161-79-6P**, N-[2-[7-(Methylthio)-1,2,3,4-tetrahydro-1-naphthalenyl]ethyl]acetamide 250161-80-9P, N-[2-[7-(Methylsulfinyl)-1,2,3,4-tetrahydro-1-naphthalenyl]ethyl]acetamide 250161-81-0P, N-[2-[7-(Methylsulfonyl)-1,2,3,4-tetrahydro-1-naphthalenyl]ethyl]acetamide 250161-82-1P, N-[2-[7-(Benzylsulfinyl)-1-naphthyl]ethyl]acetamide 250161-83-2P, N-[2-[7-(Benzylsulfonyl)-1-naphthyl]ethyl]acetamide 250161-84-3P, N-[2-(7-Mercapto-1-naphthyl)ethyl]benzamide 250161-85-4P, N-[2-(3-Benzyl-7-mercapto-1-naphthyl)ethyl]-1-cyclohexanecarboxamide 250161-86-5P, N-[2-(2-Benzyl-5-mercaptobenzo[b]furan-3-yl)ethyl]acetamide 250161-88-7P, N-[2-(2-Benzyl-5-mercaptobenzo[b]furan-3-yl)ethyl]-1-cyclopropanecarboxamide 250161-90-1P, N-[2-[7-(Allylthio)-1-naphthyl]ethyl]-2-phenylacetamide 250161-92-3P, N-[2-[7-(Benzylthio)-1-naphthyl]ethyl]heptanamide 250161-94-5P, N-Methyl-2-[7-(cyclopentylthio)-1-naphthyl]acetamide 250161-97-8P, N-Cyclohexyl-2-[7-(cyclopentylthio)-1-naphthyl]acetamide 250161-99-0P, N-[2-[7-(Allylthio)-3-phenyl-1-naphthyl]ethyl]acetamide 250162-00-6P, N-[2-[7-(Benzylthio)-3-phenyl-1-naphthyl]ethyl]acetamide 250162-01-7P, N-[3-[7-(1-Propenylthio)-1,2,3,4-tetrahydro-1-naphthalenyl]propyl]acetamide 250162-02-8P, N-[[6-(Benzylthio)-2-phenyl-2H-3-chromenyl]methyl]acetamide 250162-03-9P, N-[2-[5-(2-Pyridylthio)benzo[b]furan-3-yl]ethyl]acetamide 250162-04-0P, N-[[2-Benzyl-5-(3-butenylthio)benzo[b]thiophen-3-yl]methyl]acetamide 250162-05-1P, N-[2-[5-(Allylthio)-2-benzylbenzo[b]furan-3-yl]ethyl]-1-cyclopropanecarboxamide 250162-06-2P, N-[2-[5-(Propylthio)-2-phenylbenzo[b]thiophen-3-yl]ethyl]acetamide 250162-07-3P, N-[2-[5-(Isopentylthio)benzo[b]thiophen-3-yl]ethyl]acrylamide 250162-08-4P, N-[[2-(2-Furylmethyl)-5-(2-propynylthio)benzo[b]furan-3-yl]methyl]acetamide 250162-09-5P, N-[2-[1-Methyl-2-phenyl-5-(propylthio)-1H-pyrrolo[2,3-b]pyridin-3-yl]ethyl]acetamide 250162-10-8P, N-[4-(Butylthio)-2,3-dihydro-1H-2-phenalenyl]propanamide 250162-16-4P, N-[2-(3H-Benzo[f]thiochromen-10-yl)ethyl]-2-bromoacetamide 250162-18-6P 250162-19-7P, N-[3-(7-Methyl-7H-thiochromeno[6,5-b]furan-1-yl)propyl]acetamide 250162-20-0P, N-[2-[7-Amino-3-(cyclopropylmethyl)-1-naphthyl]ethyl]acetamide 250162-21-1P, N-[2-[7-(Diethylamino)-1-naphthyl]ethyl]-2-phenylacetamide 250162-22-2P, N-[2-[7-(Hexylamino)-1,2,3,4-tetrahydro-1-naphthalenyl]ethyl]acetamide 250162-23-3P, N-[(6-Morpholino-2-phenyl-2H-3-chromenyl)methyl]acetamide 250162-24-4P, N-[2-(3-Benzyl-3H-benzo[e]indol-9-yl)propyl]-1-cyclohexanecarboxamide 250162-25-5P, Ethyl 9-[2-[(phenylacetyl)amino]ethyl]-1-methyl-3H-benzo[e]indole-2-carboxylate 250162-26-6P, N-[2-(4-Methyl-1,2,3,4-tetrahydrobenzo[f]quinolin-10-yl)ethyl]-2-phenylacetamide 250162-27-7P,

N-[2-(1-Hydroxy-4-methyl-1,2,3,4-tetrahydrobenzo[f]quinolin-10-yl)ethyl]-2-phenylacetamide 250162-28-8P, N-[(2-Benzyl-6-ethyl-6,7-dihydrothieno[3,2-f]quinolin-1-yl)methyl]acetamide 251934-89-1P 251935-21-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of bicyclic aromatic and heteroarom. compds. as melatonin receptor ligands)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE
(1) Adir; EP 0530087 A 1993 HCAPLUS
(2) Adir; EP 0562956 A 1993 HCAPLUS
(3) Adir; EP 0662471 A 1995 HCAPLUS
(4) Adir; EP 0745583 A 1996 HCAPLUS
(5) Adir; EP 0745584 A 1996 HCAPLUS
(6) Bristol-Myers Squibb; EP 0728738 A 1996 HCAPLUS

IT **250161-68-3P**, N-[2-[7-(Methylthio)-1-naphthyl]ethyl]acetamide
250161-79-6P, N-[2-[7-(Methylthio)-1,2,3,4-tetrahydro-1-naphthalenyl]ethyl]acetamide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of bicyclic aromatic and heteroarom. compds. as melatonin receptor ligands)

RN 250161-68-3 HCAPLUS
CN Acetamide, N-[2-[7-(methylthio)-1-naphthalenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 250161-79-6 HCAPLUS
CN Acetamide, N-[2-[1,2,3,4-tetrahydro-7-(methylthio)-1-naphthalenyl]ethyl]- (9CI) (CA INDEX NAME)



=> => d his

(FILE 'HOME' ENTERED AT 12:16:19 ON 11 MAR 2004)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 12:16:34 ON 11 MAR 2004
L1 2 S (WO99-FR1100 OR FR98-5957)/AP,PRN
E LESIEUR D/AU
L2 174 S E3,E4

```
                E KLUPSCH F/AU
L3            4 S E3,E4
                E GUILLAUMET G/AU
L4          241 S E3,E4
                E VIAUD M/AU
L5           62 S E3,E4,E7-E9
                E MASSUARD M/AU
                E LANGLOIS M/AU
L6           62 S E3-E11
L7          141 S E27,E28
                E BENNEJEAN C/AU
L8           37 S E3,E4
                E RENARD P/AU
L9          401 S E3-E6,E14,E15
                E DELAGRANGE P/AU
L10         130 S E3-E6
                E DE LAGRANGE P/AU
                E DE LA GRANGE P/AU
L11           1 S E3
                E DELA GRANGE P/AU
                E LA GRANGE P/AU
                E LA GRANGE D/AU
                E LAGRANGE D/AU
L12         282 S E53-E60
                E ADIR/PA,CS
L13         425 S E3-E20
L14           2 S L1 AND L2-L13
                SEL RN

     FILE 'REGISTRY' ENTERED AT 12:20:46 ON 11 MAR 2004
L15         200 S E1-E200
L16          70 S L15 AND C6-C6/ES
L17          34 S L16 AND (N AND S)/ELS
L18          17 S L17 AND 2/NR
L19           9 S L18 AND 15/C
L20           1 S L19 AND C15H17NOS
L21           1 S L19 AND C15H21NOS
L22           2 S L20,L21
                SEL RN
L23           0 S E201-202/CRN

     FILE 'HCAOLD' ENTERED AT 12:23:10 ON 11 MAR 2004
L24           0 S L22

     FILE 'HCAPLUS' ENTERED AT 12:23:13 ON 11 MAR 2004
L25           1 S L22
L26           1 S L25 AND L1-L14

     FILE 'USPATFULL, USPAT2' ENTERED AT 12:23:36 ON 11 MAR 2004
L27           3 S L22

     FILE 'REGISTRY' ENTERED AT 12:23:46 ON 11 MAR 2004

     FILE 'USPATFULL, USPAT2' ENTERED AT 12:23:55 ON 11 MAR 2004

     FILE 'HCAPLUS' ENTERED AT 12:24:06 ON 11 MAR 2004

     FILE 'REGISTRY' ENTERED AT 12:25:10 ON 11 MAR 2004
L28         198 S L15 NOT L22
L29         179 S L28 AND NR>=2
L30         177 S L29 AND (S OR N)/ELS
L31          80 S L30 AND (OC4-C6 OR SC4-C6 OR NC4-C6 OR NOC3-C6 OR NCOC2-C6 OR
L32          10 S L30 AND (OC4-NC5 OR SC4-NC5 OR NC4-NC5 OR NOC3-NC5 OR NCOC2-N
```

```
L33           7 S L30 AND (OC5-C6 OR NC5-OC5 OR OC2OC2-C6 OR NC5-OC2OC2 OR OC2S
L34           0 S (OC2OC2-NC5 OR OC2SC2-NC5 OR SC2SC2-NC5)/ES AND L30
L35          97 S L31-L33
L36          80 S L30 NOT L35
L37          14 S L36 NOT C6-C6/ES
L38          13 S L37 NOT C15H13CLOS
L39          10 S L38 NOT (C21H21NOS2 OR C23H24N2OS OR C17H19NO2S)
L40         107 S L35,L39
L41          70 S L30 NOT L40
L42          66 S L41 AND C6-C6/ES
L43          65 S L42 NOT C10H9NO3
L44         172 S L40,L43
L45           5 S L41 NOT L44

     FILE 'HCAPLUS' ENTERED AT 12:48:54 ON 11 MAR 2004

     FILE 'REGISTRY' ENTERED AT 12:49:37 ON 11 MAR 2004
L46           3 S L45 AND NR>=3
L47         175 S L44,L46
L48         174 S L47 NOT 73-31-4

     FILE 'HCAPLUS' ENTERED AT 12:50:54 ON 11 MAR 2004
L49         103 S L48
L50          67 S L49 AND (PY<=1998 OR PRY<=1998 OR AY<=1998)
L51          29 S L50 AND L1-L14
L52          58 S L50 AND MELATONIN?
                E MELATONIN RECEPTOR/CT
                E E4+ALL
L53        1278 S E8,E7
L54          35 S L53 AND L50
L55          17 S L50 AND P/DT
L56          14 S L55 AND L51-L54
L57           3 S L55 NOT L56
L58          17 S L56,L57
L59           2 S L14 AND L58
L60          15 S L58 NOT L59

=> d all l59 tot

L59  ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2004 ACS on STN
AN   1999:736649  HCAPLUS
DN   131:336936
ED   Entered STN:  19 Nov 1999
TI   Preparation of heteroarylcarboxylates and analogs as melatonin
     receptor ligands
IN   Lesieur, Daniel; Klupsch, Frederique; Guillaumet,
     Gerald; Viaud, Marie-Claude; Langlois, Michel;
     Bennejean, Caroline; Renard, Pierre; Delagrange,
     Philippe
PA   Adir Et Compagnie, Fr.
SO   PCT Int. Appl., 131 pp.
     CODEN: PIXXD2
DT   Patent
LA   French
IC   ICM  C07C233-43
     ICS  C07C233-62; C07C237-48; C07C271-30; C07C275-24; C07C311-37;
          C07D307-81; C07D307-85; C07D311-58; C07D319-18; C07D333-58;
          C07D471-04; A61K031-165
CC   27-7 (Heterocyclic Compounds (One Hetero Atom))
     Section cross-reference(s): 1
FAN.CNT 2
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
```

PI WO 9958496 A1 19991118 WO 1999-FR1101 19990510 <--
W: AU, BR, CA, CN, HU, JP, NO, NZ, PL, US, ZA
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
FR 2778662 A1 19991119 FR 1998-5957 19980512 <--
FR 2778662 B1 20000616
CA 2331877 AA 19991118 CA 1999-2331877 19990510 <--
AU 9936104 A1 19991129 AU 1999-36104 19990510 <--
AU 747301 B2 20020516
EP 1077928 A1 20010228 EP 1999-918037 19990510 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI
JP 2002514620 T2 20020521 JP 2000-548300 19990510 <--
NZ 507692 A 20020628 NZ 1999-507692 19990510 <--
BR 9911783 A 20021231 BR 1999-11783 19990510 <--
ZA 2000006529 A 20010522 ZA 2000-6529 20001110 <--
ZA 2000006528 A 20011114 ZA 2000-6528 20001110 <--
US 6605632 B1 20030812 US 2000-700056 20001110 <--
NO 2000005715 A 20001113 NO 2000-5715 20001113 <--
US 2004002490 A1 20040101 US 2003-462326 20030616 <--
US 2004002491 A1 20040101 US 2003-462331 20030616 <--
PRAI FR 1998-5957 A 19980512 <--
WO 1999-FR1101 W 19990510
US 2000-700056 A3 20001110
OS MARPAT 131:336936
AB RZR1 [I; R = CO2H, alkoxycarbonyl, CONH2, acylamino, aminosulfonyl, etc.; R1 = alkanoylaminoalkyl, carbamoylalkyl, ureidoalkyl, etc.; Z = benzofuranylene, indolylene, naphthylene, pyrrolo[2,3-b]pyridinediyl, etc.] were prepared Thus, Me 3-bromoacetyl-4-hydroxybenzoate (preparation given)
was cyclized and the product condensed with (EtO)2P(O)CH2CN to give, after hydrolysis, title compound I. Data for biol. activity of title compds. were given.
ST heteroarylcarboxylate prepn **melatonin** receptor ligand
IT **Melatonin receptors**
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(mediated disorder; treatment; preparation of heteroarylcarboxylates and analogs as **melatonin** receptor ligands)
IT **250132-91-3P 250132-92-4P 250132-93-5P**
250132-95-7P 250132-96-8P 250132-97-9P
250132-98-0P 250132-99-1P 250133-00-7P
250133-01-8P 250133-02-9P 250133-04-1P
250133-05-2P 250133-06-3P 250133-07-4P
250133-08-5P 250133-09-6P 250133-10-9P
250133-11-0P 250133-12-1P 250133-13-2P
250133-14-3P 250133-15-4P 250133-16-5P
250133-17-6P 250133-18-7P 250133-19-8P
250133-21-2P 250133-22-3P 250133-23-4P
250133-24-5P 250133-25-6P 250133-26-7P
250133-27-8P 250133-28-9P 250133-29-0P
250133-30-3P 250133-31-4P 250133-32-5P
250133-33-6P 250133-34-7P 250133-35-8P
250133-36-9P 250133-37-0P 250133-38-1P
250133-39-2P 250133-40-5P 250133-41-6P
250133-42-7P 250133-43-8P 250133-44-9P
250133-45-0P 250133-46-1P 250133-47-2P
250133-48-3P 250133-49-4P 250133-50-7P
250133-51-8P 250133-52-9P 250133-53-0P
250133-54-1P 250133-55-2P 250133-56-3P
250133-57-4P 250133-58-5P 250133-59-6P
250133-60-9P 250133-61-0P 250133-62-1P
250133-63-2P 250133-64-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroarylcarboxylates and analogs as **melatonin** receptor ligands)

IT 100-53-8, Benzylthiol 529-34-0, 1-Tetralone 586-89-0, 4-Acetylbenzoic acid **138112-76-2 138112-77-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heteroarylcarboxylates and analogs as **melatonin** receptor ligands)

IT 16357-40-7P 40353-34-2P 71620-33-2P 74815-31-9P **152302-45-9P 156492-14-7P 229161-18-6P 250133-65-4P 250133-66-5P 250133-67-6P 250133-68-7P 250133-69-8P 250133-70-1P 250133-71-2P 250133-72-3P 250133-73-4P 250133-74-5P 250133-75-6P 250133-76-7P 250133-77-8P 250133-78-9P 250133-79-0P 250133-80-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heteroarylcarboxylates and analogs as **melatonin** receptor ligands)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Adir; EP 0530087 A 1993 HCAPLUS
(2) Adir; EP 0562956 A 1993 HCAPLUS
(3) Adir; EP 0662471 A 1995 HCAPLUS
(4) Adir; EP 0745583 A 1996 HCAPLUS
(5) Adir; EP 0745584 A 1996 HCAPLUS
(6) Bristol-Myers Squibb; EP 0728738 A 1996 HCAPLUS

L59 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:736646 HCAPLUS
DN 131:336827
ED Entered STN: 19 Nov 1999
TI Novel substituted cyclic compounds, particularly N-[2-(1-naphthyl)ethyl]acetamides and analogs with **melatonin** receptor activity, preparation method, and pharmaceutical compositions containing them
IN **Lesieur, Daniel; Klupsch, Frederique; Guillaumet, Gerald; Viaud, Marie-Claude; Langlois, Michel; Bennejean, Caroline; Renard, Pierre; Delagrange, Philippe**
PA **Adir Et Compagnie, Fr.**
SO PCT Int. Appl., 167 pp.
CODEN: PIXXD2
DT **Patent**
LA French
IC ICM C07C233-36
ICS C07C233-40; C07C317-32; C07C323-40; C07C323-41; C07C323-44; C07D209-60; C07D221-10; C07D295-12; C07D307-81; C07D333-58; C07D335-08; C07D407-12; C07D471-04; C07D495-04; A61K031-165
CC 25-24 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9958495	A1	19991118	WO 1999-FR1100	19990510	<--
	W: AU, BR, CA, CN, HU, JP, NO, NZ, PL, US, ZA					
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	FR 2778662	A1	19991119	FR 1998-5957	19980512	<--
	FR 2778662	B1	20000616			
	CA 2331870	AA	19991118	CA 1999-2331870	19990510	<--
	AU 9936103	A1	19991129	AU 1999-36103	19990510	<--

	AU 748567	B2	20020606			
	EP 1077927	A1	20010228	EP 1999-918036	19990510	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
	BR 9911771	A	20011002	BR 1999-11771	19990510	<--
	JP 2002514619	T2	20020521	JP 2000-548299	19990510	<--
	NZ 507691	A	20020531	NZ 1999-507691	19990510	<--
	ZA 2000006529	A	20010522	ZA 2000-6529	20001110	<--
	ZA 2000006528	A	20011114	ZA 2000-6528	20001110	<--
	NO 2000005714	A	20001113	NO 2000-5714	20001113	<--
PRAI	FR 1998-5957	A	19980512	<--		
	WO 1999-FR1100	W	19990510	<--		

OS MARPAT 131:336827

GI



II

AB The invention concerns compds. of formula R-A-R' [I; wherein: A = various bi- and tricyclic carbo- and heterocyclic systems; R = SH and various derivs. such as thioethers, sulfoxides, and sulfones, (un)substituted amino, or may form ring with A; R' = (CH2)nR2 where n = 0-4 and R2 = various amide-containing groups] and their stereoisomers and salts. The compds. are ligands of **melatonin** receptors, and are useful for preparing medicines for treating a variety of **melatonin**-related conditions, such as seasonal depression, anxiety, sleep and eating disorders, etc. For instance, title compound II was prepared in 7 steps: (1) acylation of thioanisole with succinic anhydride to give 4-[4-(methylthio)phenyl]-4-oxobutanoic acid; (2) reduction of oxo with Et3SiH; (3) cyclization to form a 1-naphthalenone; (4) Wittig reaction with di-Et cyanomethylphosphonate; (5) dehydrogenation with sulfur at 230°; (6) reduction of the nitrile with BH3.THF; and (7) N-acetylation of the resulting amine with AcCl. Compds. I showed little or no oral toxicity in mice, and bound strongly to mt1 and MT2 receptors in vitro, with IC50 values ≤ 10 μM. The compds. also showed circadian rhythm, anxiolytic, and vasoconstrictor/vasodilator activities in rats or in vitro.

ST naphthylethylacetamide prepn **melatonin** receptor ligand; methylthionaphthylethylacetamide prepn anxiolytic vasodilator

IT Rhythm, biological
(circadian; preparation of bicyclic aromatic and heteroarom. compds. as **melatonin** receptor ligands)

IT Appetite
Sleep
(disorder, treatment; preparation of bicyclic aromatic and heteroarom. compds. as **melatonin** receptor ligands)

IT Antidepressants
Antiobesity agents
Anxiolytics
Cardiovascular agents
Vasoconstrictors
Vasodilators
(preparation of bicyclic aromatic and heteroarom. compds. as **melatonin** receptor ligands)

IT **Melatonin receptors**
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(preparation of bicyclic aromatic and heteroarom. compds. as **melatonin** receptor ligands)

IT Insomnia
(treatment; preparation of bicyclic aromatic and heteroarom. compds. as **melatonin** receptor ligands)

IT 366-77-8P, 4-(4-Fluorophenyl)-4-oxobutanoic acid 589-06-0P, 4-(4-Fluorophenyl)butanoic acid 2840-44-0P, 7-Fluoro-3,4-dihydro-1(2H)-naphthalenone 7028-67-3P, 4-[4-(Methylthio)phenyl]-4-oxobutanoic acid **23962-24-5P**, N-[2-(5-Chlorobenzo[b]thiophen-3-yl)ethyl]acetamide **51828-63-8P**, 5-Chloro-3-methyl-2-phenyl-1-benzothiophene **51828-64-9P**, 3-(Bromomethyl)-5-chloro-2-phenyl-1-benzothiophene **65712-06-3P**, 2-(5-Chloro-2-phenyl-1-benzothiophen-3-yl)-1-ethanamine hydrochloride **65712-14-3P**, 2-(5-Chloro-2-phenyl-1-benzothiophen-3-yl)acetonitrile 116174-33-5P, 4-[4-(Methylthio)phenyl]butanoic acid **250162-30-2P**, 2-[7-(Methylthio)-1-naphthyl]-1-ethylamine hydrochloride **250162-31-3P**, 2-[7-(Methylthio)-1,2,3,4-tetrahydro-1-naphthalenylidene]acetonitrile **250162-32-4P**, N-[2-(5-Chloro-2-phenylbenzo[b]thiophen-3-yl)ethyl]acetamide **250162-33-5P**, N-[2-(5-Chlorobenzo[b]thiophen-3-yl)ethyl]acrylamide **250162-34-6P**, N-[2-(5-Chlorobenzo[b]thiophen-3-yl)ethyl]-2,2,2-trifluoroacetamide **250162-35-7P**, N-[2-(5-Chlorobenzo[b]thiophen-3-yl)ethyl]-1-cyclopropanecarboxamide **250162-37-9P**, N-[2-(5-Bromobenzo[b]thiophen-3-yl)ethyl]acetamide **250162-38-0P**, N-[2-(5-Bromobenzo[b]thiophen-3-yl)ethyl]-2,2,2-trifluoroacetamide **250162-39-1P**, N-[2-(5-Bromobenzo[b]thiophen-3-yl)ethyl]butanamide **250162-40-4P**, N-[2-(5-Bromobenzo[b]thiophen-3-yl)ethyl]-N'-methylurea **250162-41-5P**, N-[2-(5-Bromobenzo[b]thiophen-3-yl)ethyl]benzamide **250162-42-6P**, N-[2-(5-Bromobenzo[b]thiophen-3-yl)ethyl]-2-(3,4-dichlorophenyl)acetamide **250162-43-7P**, N-[2-(5-Bromobenzo[b]thiophen-3-yl)ethyl]-3-butenamide **250162-44-8P**, N-[2-(7-Fluoro-1,2,3,4-tetrahydro-1-naphthalenyl)ethyl]acetamide **250162-46-0P**, 2-(7-Fluoro-1,2,3,4-tetrahydro-1-naphthalenyl)-1-ethylamine hydrochloride **250162-47-1P**, N-[2-(5-Bromo-1-benzothiophen-3-yl)ethyl]-2-phenylacetamide **250162-48-2P**, N-[2-(5-Bromo-1-benzothiophen-3-yl)ethyl]-3,4-dichlorobenzamide **250162-49-3P**, N-[2-(5-Bromo-1-benzothiophen-3-yl)ethyl]-2-furamide **250162-50-6P**, N-[2-(5-Chloro-1-benzothiophen-3-yl)ethyl]-2-butynamide **250162-51-7P**, 4-Chloro-N-[2-(5-chloro-1-benzothiophen-3-yl)ethyl]butanamide **250162-52-8P**, N-[2-(5-Chloro-1-benzothiophen-3-yl)ethyl]-2-furamide **250162-53-9P**, N-[2-(5-Bromo-2-phenyl-1-benzothiophen-3-yl)ethyl]acetamide **250162-54-0P**, N-[2-(5-Chloro-1-benzothiophen-3-yl)ethyl]-3-phenyl-2-propenamide **250162-55-1P**, N-[2-(5-Bromo-1-benzothiophen-3-yl)ethyl]-3-phenyl-2-propenamide **250162-56-2P**, N-[2-(5-Chloro-1-benzothiophen-3-yl)ethyl]-4-phenyl-3-butenamide **250162-57-3P**, N-[2-(5-Bromo-1-benzothiophen-3-yl)ethyl]-4-phenyl-3-butenamide **250162-58-4P**, N-[2-(5-Chloro-1-benzothiophen-3-yl)ethyl]-3-butenamide **250162-59-5P**, N-[2-(5-Bromo-2-phenyl-1-benzothiophen-3-yl)ethyl]-3-butenamide **251934-90-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of bicyclic aromatic and heteroarom. compds. as **melatonin** receptor ligands)

IT 73-31-4, **Melatonin**
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(preparation of bicyclic aromatic and heteroarom. compds. as **melatonin** receptor ligands)

IT 75-08-1, Ethanethiol 98-88-4, Benzoyl chloride 100-53-8, Benzyl thiol 100-68-5, Thioanisole 107-03-9, 1-Propanethiol 108-30-5, reactions 141-75-3, Butanoyl chloride 462-06-6, Fluorobenzene 624-83-9, Methyl isocyanate 2537-48-6, Diethyl (cyanomethyl)phosphonate 4023-34-1, Cyclopropanecarboxylic acid chloride 51828-62-7, 1-[(4-Chlorophenyl)thio]-1-phenylacetone **152302-45-9**, N-[2-(7-Hydroxy-1-naphthyl)ethyl]acetamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of bicyclic aromatic and heteroarom. compds. as **melatonin** receptor ligands)

IT **250133-76-7P**, N-[2-[7-(Benzylthio)-1-naphthyl]ethyl]acetamide 250161-68-3P, N-[2-[7-(Methylthio)-1-naphthyl]ethyl]acetamide **250161-69-4P**, N-[2-[7-(Methylthio)-1-naphthyl]ethyl]butanamide **250161-70-7P**, N-[2-[7-(Methylthio)-1-naphthyl]ethyl]-1-cyclopropanecarboxamide **250161-71-8P**, N-[2-[7-(Methylthio)-1-naphthyl]ethyl]-2,2,2-trifluoroacetamide **250161-72-9P**, N-Methyl-N'-[2-[7-(methylthio)-1-naphthyl]ethyl]urea **250161-73-0P**, N-[2-[3-Benzoyl-7-(methylthio)-1-naphthyl]ethyl]acetamide **250161-74-1P**, N-[2-[3-Benzyl-7-(methylthio)-1-naphthyl]ethyl]acetamide **250161-75-2P**, N-[2-[7-(Ethylthio)-1-naphthyl]ethyl]acetamide **250161-76-3P**, N-[2-[7-(Propylthio)-1-naphthyl]ethyl]acetamide **250161-77-4P**, N-[2-[7-(Methylsulfinyl)-1-naphthyl]ethyl]acetamide **250161-78-5P**, N-[2-[7-(Methylsulfonyl)-1-naphthyl]ethyl]acetamide 250161-79-6P, N-[2-[7-(Methylthio)-1,2,3,4-tetrahydro-1-naphthalenyl]ethyl]acetamide **250161-80-9P**, N-[2-[7-(Methylsulfinyl)-1,2,3,4-tetrahydro-1-naphthalenyl]ethyl]acetamide **250161-81-0P**, N-[2-[7-(Methylsulfonyl)-1,2,3,4-tetrahydro-1-naphthalenyl]ethyl]acetamide **250161-82-1P**, N-[2-[7-(Benzylsulfinyl)-1-naphthyl]ethyl]acetamide **250161-83-2P**, N-[2-[7-(Benzylsulfonyl)-1-naphthyl]ethyl]acetamide **250161-84-3P**, N-[2-(7-Mercapto-1-naphthyl)ethyl]benzamide **250161-85-4P**, N-[2-(3-Benzyl-7-mercapto-1-naphthyl)ethyl]-1-cyclohexanecarboxamide **250161-86-5P**, N-[2-(2-Benzyl-5-mercaptobenzo[b]furan-3-yl)ethyl]acetamide **250161-88-7P**, N-[2-(2-Benzyl-5-mercaptobenzo[b]furan-3-yl)ethyl]-1-cyclopropanecarboxamide **250161-90-1P**, N-[2-[7-(Allylthio)-1-naphthyl]ethyl]-2-phenylacetamide **250161-92-3P**, N-[2-[7-(Benzylthio)-1-naphthyl]ethyl]heptanamide **250161-94-5P**, N-Methyl-2-[7-(cyclopentylthio)-1-naphthyl]acetamide **250161-97-8P**, N-Cyclohexyl-2-[7-(cyclopentylthio)-1-naphthyl]acetamide **250161-99-0P**, N-[2-[7-(Allylthio)-3-phenyl-1-naphthyl]ethyl]acetamide **250162-00-6P**, N-[2-[7-(Benzylthio)-3-phenyl-1-naphthyl]ethyl]acetamide **250162-01-7P**, N-[3-[7-(1-Propenylthio)-1,2,3,4-tetrahydro-1-naphthalenyl]propyl]acetamide **250162-02-8P**, N-[[6-(Benzylthio)-2-phenyl-2H-3-chromenyl]methyl]acetamide **250162-03-9P**, N-[2-[5-(2-Pyridylthio)benzo[b]furan-3-yl]ethyl]acetamide **250162-04-0P**, N-[[2-Benzyl-5-(3-butenylthio)benzo[b]thiophen-3-yl]methyl]acetamide **250162-05-1P**, N-[2-[5-(Allylthio)-2-benzylbenzo[b]furan-3-yl]ethyl]-1-cyclopropanecarboxamide **250162-06-2P**, N-[2-[5-(Propylthio)-2-phenylbenzo[b]thiophen-3-yl]ethyl]acetamide **250162-07-3P**, N-[2-[5-(Isopentylthio)benzo[b]thiophen-3-yl]ethyl]acrylamide **250162-08-4P**, N-[[2-(2-Furylmethyl)-5-(2-propynylthio)benzo[b]furan-3-yl]methyl]acetamide **250162-09-5P**, N-[2-[1-Methyl-2-phenyl-5-(propylthio)-1H-pyrrolo[2,3-b]pyridin-3-yl]ethyl]acetamide **250162-10-8P**, N-[4-(Butylthio)-2,3-dihydro-1H-2-phenalenyl]propanamide **250162-16-4P**, N-[2-(3H-Benzo[f]thiochromen-10-yl)ethyl]-2-bromoacetamide **250162-18-6P** **250162-19-7P**, N-[3-(7-Methyl-7H-thiochromeno[6,5-b]furan-1-yl)propyl]acetamide **250162-20-0P**, N-[2-[7-Amino-3-(cyclopropylmethyl)-1-naphthyl]ethyl]acetamide **250162-21-1P**,

N-[2-[7-(Diethylamino)-1-naphthyl]ethyl]-2-phenylacetamide **250162-22-2P**, N-[2-[7-(Hexylamino)-1,2,3,4-tetrahydro-1-naphthalenyl]ethyl]acetamide **250162-23-3P**, N-[(6-Morpholino-2-phenyl-2H-3-chromenyl)methyl]acetamide **250162-24-4P**, N-[2-(3-Benzyl-3H-benzo[e]indol-9-yl)propyl]-1-cyclohexanecarboxamide **250162-25-5P**, Ethyl 9-[2-[(phenylacetyl)amino]ethyl]-1-methyl-3H-benzo[e]indole-2-carboxylate **250162-26-6P**, N-[2-(4-Methyl-1,2,3,4-tetrahydrobenzo[f]quinolin-10-yl)ethyl]-2-phenylacetamide **250162-27-7P**, N-[2-(1-Hydroxy-4-methyl-1,2,3,4-tetrahydrobenzo[f]quinolin-10-yl)ethyl]-2-phenylacetamide **250162-28-8P**, N-[(2-Benzyl-6-ethyl-6,7-dihydrothieno[3,2-f]quinolin-1-yl)methyl]acetamide **251934-89-1P** **251935-21-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of bicyclic aromatic and heteroarom. compds. as **melatonin** receptor ligands)
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Adir; EP 0530087 A 1993 HCAPLUS
(2) Adir; EP 0562956 A 1993 HCAPLUS
(3) Adir; EP 0662471 A 1995 HCAPLUS
(4) Adir; EP 0745583 A 1996 HCAPLUS
(5) Adir; EP 0745584 A 1996 HCAPLUS
(6) Bristol-Myers Squibb; EP 0728738 A 1996 HCAPLUS

=> => d all hitstr tot

L60 ANSWER 1 OF 15 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:381460 HCAPLUS
DN 133:17374
ED Entered STN: 08 Jun 2000
TI Preparation of N-aralkylacetamides and -ureas as **melatonin** receptor ligands
IN **Lesieur, Daniel**; Depreux, Patrick; Leclerc, Veronique; Mansour, Hamid Ait; **Delagrange, Philippe**; **Renard, Pierre**
PA **Adir Et Compagnie, Fr.**
SO U.S., 23 pp., Cont.-in-part of U.S. Ser. No. 124,197.
CODEN: USXXAM
DT **Patent**
LA English
IC ICM A61K031-38
ICS A61K031-335; C07D407-02; C07D409-02; C07D491-042
NCL 514411000
CC 27-7 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 3

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	US 6071946	A	20000606		US 1999-387461	19990901	<--
	FR 2725985	A1	19960426		FR 1994-12581	19941021	<--
	FR 2725985	B1	19961115				
	US 5843986	A	19981201		US 1995-545395	19951019	<--
	US 5998461	A	19991207		US 1998-124197	19980728	<--
PRAI	FR 1994-12581	A	19941021	<--			
	US 1995-545395	A2	19951019	<--			
	US 1998-124197	A2	19980728	<--			

OS MARPAT 133:17374
GI



I

AB R1ZNR2R3 [R1 = tricyclic ring system; R2 = H or alkyl; R3 = CO(CH2)nR5, CONH(CH2)mR6, etc.; R5,R6 = H, alkyl, alkenyl, etc.; Z = (un)substituted alkylene; m,n = 0-3] were prepared as **melatonin** receptor ligands (no data). Thus, N-[2-(7-hydroxy-1-naphthyl)ethyl]acetamide was etherified by BrCH2CO2Et and the saponified product cyclized to give title compound I.

ST aralkylacetamide urea prepn **melatonin** receptor ligand

IT Sleep
(disorder, treatment; preparation of N-aralkylacetamides and -ureas as **melatonin** receptor ligands)

IT **Melatonin receptors**
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(mediated disorders; treatment; preparation of N-aralkylacetamides and -ureas as **melatonin** receptor ligands)

IT 173668-72-9P 173668-77-4P 173668-78-5P 177656-76-7P 177656-77-8P
177656-78-9P 177656-79-0P 216391-25-2P 251360-37-9P 251360-38-0P
251360-39-1P 251360-40-4P 251360-41-5P 251360-42-6P 272122-11-9P
272122-12-0P 272122-13-1P 272122-14-2P 272122-15-3P 272122-16-4P
272122-17-5P 272122-18-6P 272122-19-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-aralkylacetamides and -ureas as **melatonin** receptor ligands)

IT 105-36-2, Ethyl bromoacetate 106-95-6, Allyl bromide, reactions
106-96-7, Propargyl bromide 110-78-1, Propyl isocyanate 111-36-4, Butyl isocyanate 592-82-5, Butyl isothiocyanate 628-30-8, Propyl isothiocyanate 4747-72-2, Cyclopropyl isocyanate 6165-76-0, Propargyl tosylate 104796-21-6 229161-32-4, 2-(7-Hydroxy-1-naphthyl)ethanamine hydrochloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-aralkylacetamides and -ureas as **melatonin** receptor ligands)

IT 27404-35-9P 39581-44-7P 39581-55-0P 56798-59-5P 88612-38-8P
144705-51-1P **152302-45-9P** 173668-96-7P 177969-67-4P
177969-68-5P 177969-69-6P 177969-70-9P 251360-43-7P 251360-44-8P
251360-45-9P 251360-46-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-aralkylacetamides and -ureas as **melatonin** receptor ligands)

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Anon; EP 286515 1988 HCAPLUS
(2) Anon; EP 286516 1988 HCAPLUS
(3) Anon; EP 447285 1991 HCAPLUS
(4) Anon; EP 530087 1993 HCAPLUS
(5) Anon; EP 562956 1993 HCAPLUS
(6) Anon; WO 9529173 1995 HCAPLUS
(7) Conway, S; Society for Neuroscience 1997, V23(420), P11
(8) Glennon; Drug Development Research 1991, V22, P25 HCAPLUS

(9) Leiseur; US 5843986 1998 HCAPLUS
IT **152302-45-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-aralkylacetamides and -ureas as **melatonin** receptor ligands)
RN 152302-45-9 HCAPLUS
CN Acetamide, N-[2-(7-hydroxy-1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)



L60 ANSWER 2 OF 15 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:779227 HCAPLUS
DN 132:12253
ED Entered STN: 09 Dec 1999
TI Preparation of N-(naphthofuranylethyl)acetamides and analogs as **melatonin** receptor ligands
IN **Lesieur, Daniel**; Depreux, Patrick; Leclerc, Ve'ronique; Mansour, Hamid Ait; **Delagrange, Philippe**; **Renard, Pierre**
PA **Adir et Compagnie, Fr.**
SO U.S., 25 pp., Cont.-in-part of U.S. 5,843,986.
CODEN: USXXAM
DT **Patent**
LA English
IC ICM A61K031-34
ICS A61K031-35; C07D407-02; C07D409-02
NCL 514411000
CC 27-7 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 3

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	US 5998461	A	19991207		US 1998-124197	19980728	<--
	FR 2725985	A1	19960426		FR 1994-12581	19941021	<--
	FR 2725985	B1	19961115				
	US 5843986	A	19981201		US 1995-545395	19951019	<--
	US 6071946	A	20000606		US 1999-387461	19990901	<--
PRAI	FR 1994-12581	A	19941021	<--			
	US 1995-545395	A2	19951019	<--			
	US 1998-124197	A2	19980728	<--			

OS MARPAT 132:12253
GI



I



II

AB Title compds. [I; RR1 = (un)substituted (oxo)alk(en)ylene,

-(oxo)alkynylene; R2 = H or alkyl; R3 = CO(CH2)nR5, CONH(CH2)mR6, etc.; R5,R6 = H, (cyclo)alkyl, alkenyl, etc.; Z = CH:CHCH:CH, CH:CHX, etc.; X = O, S, NH; Z1(un)substituted alkylene; m,n = 0-3] were prepared Thus, N-[2-(7-hydroxy-1-naphthyl)ethyl]acetamide was etherified by BrCH2Co2Et and the saponified product cyclized to give title compound II. Data for biol. activity of I were given.

ST naphthofuranylethylacetamide prepn **melatonin** receptor ligand

IT **Melatonin receptors**
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(mediated disorders; treatment; preparation of N-(naphthofuranylethyl)acetamides and analogs as **melatonin** receptor ligands)

IT Anxiolytics
(preparation of N-(naphthofuranylethyl)acetamides and analogs as **melatonin** receptor ligands)

IT 173668-72-9P 173668-77-4P 173668-78-5P 177656-76-7P 177656-77-8P
177656-78-9P 177656-79-0P 216391-25-2P 251360-35-7P 251360-37-9P
251360-38-0P 251360-39-1P 251360-40-4P 251360-41-5P 251360-42-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(naphthofuranylethyl)acetamides and analogs as **melatonin** receptor ligands)

IT 105-36-2, Ethyl bromoacetate 106-95-6, Allyl bromide, reactions
106-96-7, Propargyl bromide 107-19-7, Propargyl alcohol 104796-21-6
139525-77-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-(naphthofuranylethyl)acetamides and analogs as **melatonin** receptor ligands)

IT 27404-35-9P 39581-44-7P 39581-55-0P 56798-59-5P 88612-38-8P
144705-51-1P **152302-45-9P** 173668-96-7P 177969-67-4P
177969-68-5P 177969-69-6P 177969-70-9P 251360-43-7P 251360-44-8P
251360-45-9P 251360-46-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-(naphthofuranylethyl)acetamides and analogs as **melatonin** receptor ligands)

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE
(1) Anon; EP 286515 1988 HCAPLUS
(2) Anon; EP 286516 1988 HCAPLUS
(3) Anon; EP 447285 1991 HCAPLUS
(4) Anon; EP 530087 1993 HCAPLUS
(5) Anon; EP 562956 1993 HCAPLUS
(6) Anon; WO 95/29173 1995 HCAPLUS
(7) Conway, S; Society for Neuroscience 1997, P23
(8) Glennon; Drug Development Research 1991, V22, P25 HCAPLUS
(9) Leiseur; US 5843986 1998 HCAPLUS

IT **152302-45-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-(naphthofuranylethyl)acetamides and analogs as **melatonin** receptor ligands)

RN 152302-45-9 HCAPLUS

CN Acetamide, N-[2-(7-hydroxy-1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)



L60 ANSWER 3 OF 15 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:613901 HCAPLUS
DN 131:228718
ED Entered STN: 26 Sep 1999
TI Preparation of indoloquinolizinones and related compounds for treatment of stress, anxiety, depression, insomnia, schizophrenia, psychoses, and epilepsy.
IN Fourtillan, Jean-Bernard; Fourtillan, Marianne; Jacquesy, Jean-Claude; Jouannetaud, Marie-Paule; Violeau, Bruno; Karam, Omar
PA Cemaf, Fr.; Laboratoires Besins Iscovesco
SO PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM C07D471-04
ICS C07D221-04; A61K031-435
CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9947521	A1	19990923	WO 1999-IB494	19990317 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6048868	A	20000411	US 1998-42990	19980317 <--
	CA 2324270	AA	19990923	CA 1999-2324270	19990317 <--
	AU 9932707	A1	19991011	AU 1999-32707	19990317 <--
	AU 752364	B2	20020919		
	BR 9908833	A	20001121	BR 1999-8833	19990317 <--
	EP 1064284	A1	20010103	EP 1999-939844	19990317 <--
	EP 1064284	B1	20020327		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002506867	T2	20020305	JP 2000-536716	19990317 <--
	AT 215087	E	20020415	AT 1999-939844	19990317 <--
	PT 1064284	T	20020930	PT 1999-99939844	19990317 <--
	ES 2174632	T3	20021101	ES 1999-939844	19990317 <--
	CN 1115342	B	20030723	CN 1999-805687	19990317 <--
	NZ 506913	A	20030725	NZ 1999-506913	19990317 <--
	RU 2210571	C2	20030820	RU 2000-126288	19990317 <--
	BG 104768	A	20010531	BG 2000-104768	20000914 <--
	BG 63973	B1	20030829		
	NO 2000004638	A	20001116	NO 2000-4638	20000915 <--
PRAI	US 1998-42990	A	19980317 <--		
	FR 1994-10964	A	19940914 <--		
	WO 1999-IB494	W	19990317		

OS MARPAT 131:228718
GI



I

AB Title compds. [I; X = NR5, CR6:CR7; R1-R4 = H, OH, alkyl, alkoxy, aryl, aryloxy, halo, NO2, alkylcarbonyl, alkylcarbonyloxy, CO2H, aminoalkyl, etc.; adjacent pairs of R1-R4 = (oxo)-2,3-dihydropyranyl; R5 = H, alkyl, cycloalkyl, aryl, aralkyl, alkoxy, alkylcarbonyl, haloalkylcarbonyl, alkyloxycarbonyl, amino, etc.; R6, R7, R9, R10, R12, R13, R14, R15 = H, alkyl, cycloalkyl, haloalkyl, perhaloalkyl, aryl, aralkyl, alkoxy, cycloalkoxy, haloalkoxy, aryloxy, aralkyloxy, hydroxyalkyl, alkyloxyalkyl, alkylthio, cycloalkylthio, etc.; R8 = alkyl, cycloalkyl, hydroxyalkyl, alkyloxyalkyl, haloalkyl, aryl, etc.; R11 = O, S; dotted lines = optional double bonds], were prepared for treatment of diseases associated with disorders of **melatonin** activity. Thus, acrylic acid and 1-propyl-6-methoxy-3,4-dihydro-2-carboline in DMF were treated with diphenylphosphoryl azide and Et3N to give 9-methoxy-1-ethyl-2,3,4,6,7,12-hexahydroindolo[2,3-a]quinazolin-4-one. The latter at 5 μmol/kg orally in dogs increased sleep time from 9.9 min./120 min. observation period to 40.4 min./120 min. observation period.

ST indoloquinolizinone stress anxiety depression insomnia schizophrenia psychoses epilepsy treatment; **melatonin** disorder treatment indoloquinolizinone

IT Nervous system
(degeneration, treatment; preparation of indoloquinolizinones and related compds. for treatment of stress, anxiety, depression, insomnia, schizophrenia, psychoses, and epilepsy)

IT Anticonvulsants
Antidepressants
Antipsychotics
Antitumor agents
Anxiolytics
Hypnotics and Sedatives
(preparation of indoloquinolizinones and related compds. for treatment of stress, anxiety, depression, insomnia, schizophrenia, psychoses, and epilepsy)

IT 244080-24-8P 244080-25-9P 244080-26-0P 244080-27-1P 244080-28-2P
244080-29-3P 244080-30-6P 244080-31-7P 244080-32-8P 244080-33-9P
244080-34-0P 244080-35-1P 244080-36-2P 244080-37-3P 244080-38-4P
244080-39-5P 244080-40-8P 244080-41-9P 244080-42-0P 244080-43-1P
244080-44-2P 244080-45-3P 244080-46-4P 244080-47-5P 244080-48-6P
244080-49-7P 244080-50-0P 244080-51-1P 244080-52-2P 244080-53-3P
244080-54-4P 244080-55-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indoloquinolizinones and related compds. for treatment of stress, anxiety, depression, insomnia, schizophrenia, psychoses, and epilepsy)

IT 79-10-7, 2-Propenoic acid, reactions 608-07-1, 5-Methoxytryptamine
814-68-6, 2-Propenoyl chloride **138112-77-3** 138112-99-9

244080-56-6 244080-57-7 244080-58-8 244080-59-9 244080-60-2
244080-61-3 244080-62-4 244080-63-5 244080-64-6 244080-65-7
244080-66-8 244080-67-9 244080-68-0 244080-69-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of indoloquinolizinones and related compds. for treatment of stress, anxiety, depression, insomnia, schizophrenia, psychoses, and epilepsy)

IT 79-10-7, 2-Propenoic acid, reactions 608-07-1, 5-Methoxytryptamine
814-68-6, 2-Propenoyl chloride **138112-77-3** 138112-99-9
244080-56-6 244080-57-7 244080-58-8 244080-59-9 244080-60-2
244080-61-3 244080-62-4 244080-63-5 244080-64-6 244080-65-7
244080-66-8 244080-67-9 244080-68-0 244080-69-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of indoloquinolizinones and related compds. for treatment of stress, anxiety, depression, insomnia, schizophrenia, psychoses, and epilepsy)

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Benovsky, P; Tetrahedron Letters 1997, V38(49), P8475 HCAPLUS
(2) Bosling, E; Chemische Berichte 1979, V112, P1902
(3) Cemaf Et Laboratoires Besins Iscovesco; WO 9608490 A 1996 HCAPLUS
(4) Danieli, B; Gazzetta Chimica Italiana 1981, V111, P257 HCAPLUS
(5) Danieli, B; Synthesis 1984, V4, P353
(6) Dansco, A; Acta Chimica Hungarica 1986, V123(3), P155
(7) Dubocovich; US 5283343 A 1994 HCAPLUS
(8) Hammer, H; Chemische Berichte 1979, V112, P1889 HCAPLUS
(9) Hammer, H; Tetrahedron 1981, V37(21), P3609 HCAPLUS
(10) Harley-Mason, J; Journal of the Chemical Society Chemical Communications 1967, V1967, P915
(11) Ihara, M; Heterocycles 1985, V23(1), P221
(12) Ihara, M; Journal of the Chemical Society Chemical Communications 1995, V1995, P2085
(13) Incze, M; Archive Der Pharmazie 1990, V323, P331 HCAPLUS
(14) Kalaus, G; Chemische Berichte 1981, V114, P1476 HCAPLUS
(15) Kalaus, G; Journal of Organic Chemistry 1978, V43(26), P5017 HCAPLUS
(16) Laronze, J; Bulletin of the Chemical Society of France 1977, V1977, P1215
(17) Mandal, S; Journal of Organic Chemistry 1988, V53(18), P4236 HCAPLUS
(18) Massiot, G; Tetrahedron Letters 1982, V23(2), P177 HCAPLUS
(19) Node, M; Journal of Organic Chemistry 1990, V55, P517 HCAPLUS
(20) Stoit, A; Tetrahedron 1989, V45(3), P849 HCAPLUS
(21) Takayama, H; Tetrahedron Letters 1994, V35(47), P8813 HCAPLUS

IT **138112-77-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of indoloquinolizinones and related compds. for treatment of stress, anxiety, depression, insomnia, schizophrenia, psychoses, and epilepsy)

RN 138112-77-3 HCAPLUS
CN Benzeneacetamide, N-[2-(7-methoxy-1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)



L60 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:355613 HCAPLUS
DN 131:5112
ED Entered STN: 10 Jun 1999
TI Preparation of N-[2-(1-naphthyl)ethyl]acetamides and analogs as **melatonin** receptor ligands
IN Lefoulon, Francois; Demuynck, Luc; **Lesieur, Daniel**; Depreux, Patrick; **Bennejean, Caroline**; **Renard, Pierre**; **Delagrange, Philippe**
PA **Adir et Compagnie, Fr.**
SO Eur. Pat. Appl., 44 pp.
CODEN: EPXXDW
DT **Patent**
LA French
IC ICM C07C233-22
ICS C07C233-05; C07C233-60; C07C233-58; C07C233-31; A61K031-16; C07C309-65; C07D307-12; C07D333-16
CC 25-24 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 919541	A1	19990602	EP 1998-402963	19981127 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	FR 2771739	A1	19990604	FR 1997-14975	19971128 <--
	FR 2771739	B1	20010420		
	US 6143789	A	20001107	US 1998-199531	19981125 <--
	NO 9805516	A	19990531	NO 1998-5516	19981126 <--
	CA 2254658	AA	19990528	CA 1998-2254658	19981127 <--
	AU 9894213	A1	19990617	AU 1998-94213	19981127 <--
	AU 757436	B2	20030220		
	CN 1221734	A	19990707	CN 1998-122715	19981127 <--
	BR 9805031	A	20000328	BR 1998-5031	19981127 <--
	NZ 333046	A	20000428	NZ 1998-333046	19981127 <--
	JP 11263761	A2	19990928	JP 1998-338669	19981130 <--
	ZA 9810872	A	19990601	ZA 1998-10872	19990601 <--
PRAI	FR 1997-14975	A	19971128 <--		

OS MARPAT 131:5112
AB RZZ1R1 [I; R = halo, alkyl, alkanoyloxy, aryl, etc.; R1 = NR2COR21, NR2CONHR21, CONR2R21, etc.; R2 = H or alkyl; R21 = alk(en)yl, aryl, C6H4Ph, etc.; Z = (un)substituted 2-8,1-naphthylene, -1,2-, -2,3- (sic), or -1,4-dihydronaphthylene; Z1 = (un)substituted alkylene] were prepared Thus, N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide was converted in 4 steps to N-[2-(7-methoxy-3-phenyl-1-naphthyl)ethyl]acetamide. Data for biol. activity of I were given.
ST naphthylethylacetamide prepn **melatonin** receptor ligand; nervous system agent naphthylethylacetamide prepn
IT Nervous system agents
(preparation of N-[2-(1-naphthyl)ethyl]acetamides and analogs as **melatonin** receptor ligands)
IT **Melatonin receptors**
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(preparation of N-[2-(1-naphthyl)ethyl]acetamides and analogs as **melatonin** receptor ligands)
IT 225785-66-0P 225785-68-2P 225785-70-6P 225785-72-8P 225785-74-0P
225785-76-2P 225785-78-4P 225785-79-5P 225785-81-9P 225785-83-1P
225785-84-2P 225785-86-4P 225785-87-5P 225785-89-7P 225785-91-1P
225785-92-2P 225785-93-3P 225785-98-8P 225786-01-6P 225786-04-9P
225786-06-1P 225786-08-3P 225786-11-8P 225786-14-1P 225786-16-3P
225786-17-4P 225786-22-1P 225786-23-2P 225786-25-4P 225786-26-5P
225786-27-6P 225786-30-1P 225786-32-3P 225786-34-5P 225786-38-9P
225786-40-3P 225786-42-5P 225786-44-7P 225786-45-8P 225786-46-9P

225786-50-5P 225786-51-6P 225786-52-7P 225786-55-0P 225786-58-3P
225786-61-8P 225786-64-1P 225786-66-3P 225786-69-6P 225786-72-1P
225786-74-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[2-(1-naphthyl)ethyl]acetamides and analogs as **melatonin** receptor ligands)

IT 98-80-6, Phenylboronic acid **138112-76-2** 152302-33-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-[2-(1-naphthyl)ethyl]acetamides and analogs as **melatonin** receptor ligands)

IT 166526-96-1P 166526-99-4P 225786-75-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-[2-(1-naphthyl)ethyl]acetamides and analogs as **melatonin** receptor ligands)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) ADIR; EP 0745584 A 1996 HCAPLUS
(2) ADIR; EP 0745586 A 1996 HCAPLUS
(3) Adir; EP 0662471 A 1995 HCAPLUS
(4) Adir; EP 0721938 A 1996 HCAPLUS
(5) Adir; EP 0745583 A 1996 HCAPLUS
(6) Bristol-Myers Squibb; EP 0728738 A 1996 HCAPLUS
(7) Kaltenbronn J; US 3467710 A 1969 HCAPLUS
(8) Takeda Chemical Industries Ltd; WO 9608466 A 1996 HCAPLUS

IT **138112-76-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-[2-(1-naphthyl)ethyl]acetamides and analogs as **melatonin** receptor ligands)

RN 138112-76-2 HCAPLUS
CN Acetamide, N-[2-(7-methoxy-1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)



L60 ANSWER 5 OF 15 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:671173 HCAPLUS
DN 127:252983
ED Entered STN: 23 Oct 1997
TI **Melatonin** or analogs for the treatment of sensitive skin
IN De Lacharriere, Olivier; Breton, Lionel
PA L'Oreal S. A., Fr.
SO Fr. Demande, 25 pp.
CODEN: FRXXBL
DT **Patent**
LA French
IC ICM A61K031-40
ICS A61K007-48; C07D209-32
CC 62-4 (Essential Oils and Cosmetics)
Section cross-reference(s): 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 2741802	A1	19970606	FR 1995-14319	19951204 <--

FR 2741802 B1 19980102
PRAI FR 1995-14319 19951204 <--
AB **Melatonin** or analogs for the treatment of sensitive skin in cosmetic or pharmaceuticals are described. Thus, a cosmetic cream contained **melatonin** 0.01, cetyl alc. 2.00, glyceryl stearate 2.00, stearic acid 2.00, polyglyceryl 3-hydroxylauryl ether 5.00, mineral oil 12.00, Carbomer 0.35, NaOH 0.15, perfume qs, methylparaben 0.20, and water to 100.0%.
ST **melatonin** analog skin cosmetic
IT Cosmetics
Cosmetics
(cleansing creams; **melatonin** or analogs for treatment of sensitive skin)
IT Cosmetics
(creams, wrinkle-preventing; **melatonin** or analogs for treatment of sensitive skin)
IT Cosmetics
(creams; **melatonin** or analogs for treatment of sensitive skin)
IT Cosmetics
(emulsions; **melatonin** or analogs for treatment of sensitive skin)
IT Drug delivery systems
(gels, topical; **melatonin** or analogs for treatment of sensitive skin)
IT Cosmetics
(gels; **melatonin** or analogs for treatment of sensitive skin)
IT Cosmetics
(lotions; **melatonin** or analogs for treatment of sensitive skin)
IT Cosmetics
Erythema
Shampoos
Skin
(**melatonin** or analogs for treatment of sensitive skin)
IT Peptides, biological studies
Salts, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**melatonin** or analogs for treatment of sensitive skin)
IT Drug delivery systems
(topical; **melatonin** or analogs for treatment of sensitive skin)
IT 58-82-2, Bradykinin 33507-63-0, Substance P 83652-28-2, CGRP
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antagonists; **melatonin** or analogs for treatment of sensitive skin)
IT 73-31-4, **Melatonin** 608-07-1, 5-Methoxytryptamine 712-09-4, 5-Methoxytryptophol 2208-41-5, 6-Hydroxymelatonin 3471-31-6, 5-Methoxyindole-3-acetic acid 28052-84-8, 5-Methoxytryptophan **138112-76-2** 195812-34-1
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**melatonin** or analogs for treatment of sensitive skin)
IT **138112-76-2**
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**melatonin** or analogs for treatment of sensitive skin)
RN 138112-76-2 HCAPLUS
CN Acetamide, N-[2-(7-methoxy-1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)



L60 ANSWER 6 OF 15 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:667174 HCAPLUS
DN 127:252981
ED Entered STN: 22 Oct 1997
TI **Melatonin** or analogs for the treatment of skin disorders and fatigue state
IN De Lacharriere, Olivier; Breton, Lionel
PA L'Oreal S. A., Fr.
SO Fr. Demande, 12 pp.
CODEN: FRXXBL
DT **Patent**
LA French
IC ICM A61K007-48
ICS A61K031-40
CC 62-4 (Essential Oils and Cosmetics)
Section cross-reference(s): 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 2741799	A1	19970606	FR 1995-14320	19951204 <--
FR 2741799	B1	19980102		
PRAI FR 1995-14320		19951204 <--		

AB The use of **melatonin** or analogs in a cosmetic composition or the treatment of skin disorders and fatigue state is described. Thus, a face cream (oil-in-water) contained **melatonin** 1.00, glycerol stearate 2.00, Polysorbate 60 1.00, stearic acid 1.40, triethanolamine 0.70, Carbome 0.40, a liquid fraction f shea butter 12.00, perhydrosqualne 12.00, antioxidant 0.05, perfume 0.5, preservative 0.30, and water to 100%.
ST **melatonin** analog skin fatigue cosmetic; emulsion cream
melatonin analog skin
IT Cosmetics
(creams; **melatonin** or analogs for treatment of skin disorders and fatigue state)
IT Cosmetics
(emulsions; **melatonin** or analogs for treatment of skin disorders and fatigue state)
IT Cosmetics
(gels; **melatonin** or analogs for treatment of skin disorders and fatigue state)
IT Acne
Pruritus
Seborrhea
(inhibitors; **melatonin** or analogs for treatment of skin disorders and fatigue state)
IT Cosmetics
(lotions; **melatonin** or analogs for treatment of skin disorders and fatigue state)
IT Anesthetics
Anti-inflammatory agents
Antibacterial agents
Antiviral agents
Fatigue, biological
Fungicides
Parasiticides

Skin, disease
(**melatonin** or analogs for treatment of skin disorders and fatigue state)

IT 58-82-2, Bradykinin 33507-63-0, Substance P 83652-28-2, CGRP
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antagonists; **melatonin** or analogs for treatment of skin disorders and fatigue state)

IT **138112-76-2** 195812-34-1
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**melatonin** or analogs for treatment of skin disorders and fatigue state)

IT 73-31-4, **Melatonin** 608-07-1, 5-Methoxytryptamine 712-09-4, 5-Methoxytryptophol 2208-41-5, 6-Hydroxymelatonin 3471-31-6, 5-Methoxyindole-3-acetic acid 28052-84-8, 5-Methoxytryptophan
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**melatonin** or analogs for treatment of skin disorders and fatigue state)

IT **138112-76-2**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**melatonin** or analogs for treatment of skin disorders and fatigue state)

RN 138112-76-2 HCAPLUS
CN Acetamide, N-[2-(7-methoxy-1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)



L60 ANSWER 7 OF 15 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:69632 HCAPLUS
DN 126:89158
ED Entered STN: 31 Jan 1997
TI Preparation of alkoxy aryl compounds with affinity to **melatonin** receptors and pharmaceutical compositions containing them
IN **Lesieur, Daniel**; Depreux, Patrick; Leclerc, Veronique; Delagrance, Philippe; **Renard, Pierre**
PA **Adir Et Compagnie, Fr.**
SO Eur. Pat. Appl., 30 pp.
CODEN: EPXXDW
DT **Patent**
LA French
IC ICM C07C233-18
ICS C07C275-24; C07C335-12; C07D209-16; C07D333-58; C07D307-81; A61K031-165; A61K031-17; A61K031-40; A61K031-38; A61K031-34
CC 25-24 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 745583	A1	19961204	EP 1996-401158	19960530 <--
EP 745583	B1	19991229		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
FR 2734814	A1	19961206	FR 1995-6434	19950531 <--

	FR 2734814	B1	19970704			
	JP 08325217	A2	19961210	JP 1996-128136	19960523	<--
	AU 9654559	A1	19961212	AU 1996-54559	19960529	<--
	AU 704023	B2	19990415			
	CA 2177743	AA	19961201	CA 1996-2177743	19960530	<--
	CA 2177743	C	20000808			
	NO 9602207	A	19961202	NO 1996-2207	19960530	<--
	CN 1145896	A	19970326	CN 1996-107790	19960530	<--
	CN 1064674	B	20010418			
	US 5668180	A	19970916	US 1996-655439	19960530	<--
	AT 188207	E	20000115	AT 1996-401158	19960530	<--
	ES 2143154	T3	20000501	ES 1996-401158	19960530	<--
	ZA 9604484	A	19961212	ZA 1996-4484	19960531	<--
	GR 3032289	T3	20000427	GR 1999-403251	19991230	<--
PRAI	FR 1995-6434	A	19950531	<--		

OS MARPAT 126:89158

GI



I

AB I [R1 = C1-4 alkylene chain, optionally substituted; R2 = H, alkyl; R3 = C(X)(CH2)nR5 (n = 0-3, X = O, S and R5 = H, alkyl, alkenyl, alkynyl, cycloalkyl, dicycloalkylalkyl), C(X')NH(CH2)mR6 (X' = O, S, m = 0-3, R6 = H, alkyl, alkenyl, alkynyl, cycloalkyl, dicycloalkylalkyl); A = alkyl, alkenyl, alkynyl; R = alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, diarylalkyl, cycloalkenyl, cycloalkenylalkyl; Y forms (with the benzo part) naphthalene, benzofuran, benzothiophene, indole] were prepared and their affinity for **melatonin** receptors studied (no data). E.g., N-[2-(7-hydroxy-1-naphthyl)ethyl]acetamide was allylated with allyl bromide, then heated in N,N-dimethylaniline and methylated to give N-[2-(7-methoxy-8-allyl-1-naphthyl)ethyl]acetamide.

ST alkoxy aryl compd prepn **melatonin** receptor; methoxyallylnaphthylethylacetamide prepn **melatonin** receptor affinity; naphthylethylacetamide methoxyallyl prepn **melatonin** receptor affinity; acetamide methoxyallylnaphthylethyl prepn **melatonin** receptor affinity

IT **Melatonin receptors**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(preparation of alkoxy aryl compds. with affinity to **melatonin** receptors)

IT 185543-04-8P 185543-07-1P 185543-10-6P 185543-13-9P 185543-16-2P 185543-18-4P 185543-20-8P 185543-22-0P 185543-24-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of alkoxy aryl compds. with affinity to **melatonin** receptors)

IT 106-95-6, Allyl bromide, reactions 139525-77-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of alkoxy aryl compds. with affinity to **melatonin** receptors)

IT 144705-51-1P **152302-45-9P** 177969-69-6P 177969-70-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of alkoxy aryl compds. with affinity to **melatonin** receptors)

IT **152302-45-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of alkoxy aryl compds. with affinity to **melatonin** receptors)

RN 152302-45-9 HCAPLUS

CN Acetamide, N-[2-(7-hydroxy-1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)



L60 ANSWER 8 OF 15 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1996:377034 HCAPLUS

DN 125:58321

ED Entered STN: 29 Jun 1996

TI Preparation of N-[(hetero)arylethyl]acetamides and analogs as **melatonin** receptor ligands

IN **Lesieur, Daniel**; Depreux, Patrick; Leclerk, Veronique; Ait Mansour, Hamid; **Delagrange, Philippe**; **Renard, Pierre**

PA **Adir Et Compagnie, Fr.**

SO Eur. Pat. Appl., 38 pp.
CODEN: EPXXDW

DT **Patent**

LA French

IC ICM C07D307-92
ICS C07D491-04; C07C233-18; C07C275-22; C07D311-92; C07D495-04; C07D493-04; A61K031-34

ICI C07D491-04, C07D311-00, C07D209-00; C07D495-04, C07D333-00, C07D311-00; C07D493-04, C07D311-00, C07D307-00

CC 27-14 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI EP 708099	A1	19960424	EP 1995-402331	19951019	<--
EP 708099	B1	20011128			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
FR 2725985	A1	19960426	FR 1994-12581	19941021	<--
FR 2725985	B1	19961115			
NO 9504149	A	19960422	NO 1995-4149	19951018	<--
CA 2160961	AA	19960422	CA 1995-2160961	19951019	<--
CA 2160961	C	20010717			
AT 209641	E	20011215	AT 1995-402331	19951019	<--
PT 708099	T	20020531	PT 1995-95402331	19951019	<--
ES 2169113	T3	20020701	ES 1995-402331	19951019	<--
FI 9505023	A	19960422	FI 1995-5023	19951020	<--
AU 9534377	A1	19960502	AU 1995-34377	19951020	<--
AU 688586	B2	19980312			
ZA 9508894	A	19960514	ZA 1995-8894	19951020	<--
CN 1130184	A	19960904	CN 1995-115980	19951020	<--
CN 1053662	B	20000621			
JP 08239377	A2	19960917	JP 1995-272750	19951020	<--
JP 2999143	B2	20000117			
CN 1263095	A	20000816	CN 1999-126158	19991215	<--

PRAI FR 1994-12581 A 19941021 <--
OS MARPAT 125:58321
GI



I



II

AB Title compds. [I; RR1 = OZ2; R2 = H or alkyl; R3 = C(:X)Z3(CH2)nR4; R4 = H, alk(en)yl, cycloalkyl, etc.; X = O or S; Z = atoms to form a benzene, furan, thiophene ring, etc.; Z1 = (un)substituted alkylene; Z2 = (un)substituted alk(en)ylene, alkynylene; Z3 = bond or NH; n = 0-3] were prepared Thus, 2-(7-methoxy-1-naphthyl)ethylamine was converted in 5 steps to title compound II which had IC50 of 6.9x10-15M against iodomelatonin binding at sheep pars tuberalis preparation in vitro.

ST arylethylacetamide prepn **melatonin** receptor ligand

IT **Receptors**
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(**melatonin**, mediated conditions; treatment; preparation of N-[(hetero)arylethyl]acetamides and analogs as **melatonin** receptor ligands)

IT 173668-72-9P 173668-77-4P 173668-78-5P 177656-76-7P 177656-77-8P 177656-78-9P 177656-79-0P 177969-66-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[(hetero)arylethyl]acetamides and analogs as **melatonin** receptor ligands)

IT 105-36-2, Ethyl bromoacetate 106-95-6, Allyl bromide, reactions 6165-76-0, Propargyl tosylate 139525-77-2 177969-71-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-[(hetero)arylethyl]acetamides and analogs as **melatonin** receptor ligands)

IT 144705-51-1P **152302-45-9P** 173668-96-7P 177969-67-4P 177969-68-5P 177969-69-6P 177969-70-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-[(hetero)arylethyl]acetamides and analogs as **melatonin** receptor ligands)

IT **152302-45-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-[(hetero)arylethyl]acetamides and analogs as **melatonin** receptor ligands)

RN 152302-45-9 HCAPLUS
CN Acetamide, N-[2-(7-hydroxy-1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)



L60 ANSWER 9 OF 15 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:998357 HCAPLUS
DN 124:175848
ED Entered STN: 22 Dec 1995
TI Preparation of benzo-fused 5-membered heterocyclic compound 5-HT1 receptor antagonist analgesics for the treatment of migraine headaches
IN North, Peter Charles; Wadman, Sjoerd Nicolaas; Ladlow, Mark
PA Glaxo Group Ltd., UK
SO PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM C07D405-04
ICS C07D405-14; C07D413-14; C07D417-04; C07D413-04; C07D409-04; C07D413-06; C07D401-04; C07D401-14; A61K031-34; A61K031-44; C07D213-38; C07D271-10; C07D249-08
CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9528400	A1	19951026	WO 1995-EP1315	19950412 <--
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9523439	A1	19951110	AU 1995-23439	19950412 <--
PRAI	GB 1994-7447		19940414 <--		
	WO 1995-EP1315		19950412 <--		

OS MARPAT 124:175848
GI



I

AB The title compds. [I; A = O, S, (un)substituted NH, CH:CH; B = N or (un)substituted CH; C = bond, C1-3 alkylidene; D = (un)substituted NH2; D = (un)substituted heterocyclyl; E = (un)substituted 5- or 6- membered heterocyclyl] [e.g., 5-[3-(2-aminoethyl)-5-benzofuranyl]-3-pyridinemethanol], useful as selective 5-HT1 receptor antagonists (no data) for the treatment of migraine headache pain (no data), are prepared

ST aminoethylbenzofuranylpyridinemethanol prepn analgesic migraine headache treatment; aminoethylbenzofuranyl pyridinemethanol; pyridinemethanol aminoethylbenzofuranyl; neurotransmitter antagonist serotoninergic prepn aminoethylbenzofuranylpyridinemethanol

IT Headache
(benzo-fused 5-membered heterocyclic compound 5-HT1 receptor antagonist analgesics for treatment of)
IT Analgesics
(benzo-fused 5-membered heterocyclic compound 5-HT1 receptor antagonists)
IT Headache
(migraine, benzo-fused 5-membered heterocyclic compound 5-HT1 receptor antagonist analgesics for treatment of)
IT Neurotransmitter antagonists
(serotoninergic S1, benzo-fused 5-membered heterocyclic compds.)
IT 75-31-0, 2-Propanamine, reactions 78-94-4, 3-Buten-2-one, reactions
79-44-7 98-09-9, Benzenesulfonyl chloride 98-88-4, Benzoyl chloride
108-24-7 120-93-4, 2-Imidazolidinone 497-25-6, 2-Oxazolidinone
543-27-1 594-44-5, Ethanesulfonyl chloride 625-92-3 1633-82-5
1885-14-9 3430-16-8 4635-59-0 5419-55-6 6134-61-8 10147-37-2,
2-Propanesulfonyl chloride 13528-93-3 16640-68-9 26386-88-9
29681-44-5 33674-96-3 37669-64-0 38870-89-2 38940-62-4
39741-46-3 39891-08-2 39891-12-8 54450-20-3 57871-48-4
62285-48-7 66715-65-9, 2-Pyridinesulfonyl chloride 71620-34-3
88139-91-7 146679-66-5 152351-91-2 156423-67-5 173999-05-8
173999-06-9 173999-07-0 173999-08-1 173999-09-2 173999-10-5
173999-11-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzo-fused 5-membered heterocyclic compound 5-HT1 receptor antagonist analgesics for the treatment of migraine headaches)
IT 20986-40-7P 28733-43-9P 73335-64-5P 104290-45-1P 135124-70-8P
139313-83-0P 156423-63-1P 156423-64-2P 156423-66-4P
156492-14-7P 173999-12-7P 173999-13-8P 173999-14-9P
173999-15-0P 173999-16-1P 173999-17-2P 173999-18-3P 173999-19-4P
173999-20-7P 173999-21-8P 173999-22-9P 173999-23-0P 173999-24-1P
173999-26-3P 173999-27-4P 173999-28-5P 173999-29-6P 173999-30-9P
173999-31-0P 173999-32-1P 173999-33-2P 173999-34-3P 173999-35-4P
173999-36-5P 173999-37-6P 173999-38-7P 173999-39-8P 173999-40-1P
173999-41-2P 173999-42-3P 173999-43-4P 173999-44-5P 173999-45-6P
173999-46-7P 173999-47-8P 173999-48-9P 173999-49-0P 173999-50-3P
173999-51-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzo-fused 5-membered heterocyclic compound 5-HT1 receptor antagonist analgesics for the treatment of migraine headaches)
IT 156423-61-9P 173999-03-6P 173999-04-7P 173999-52-5P 173999-53-6P
173999-54-7P 173999-55-8P 173999-56-9P 173999-58-1P 173999-59-2P
173999-60-5P 173999-61-6P 173999-62-7P 173999-63-8P 173999-64-9P
173999-65-0P 173999-66-1P 173999-67-2P 173999-68-3P 173999-70-7P
173999-71-8P 173999-72-9P 173999-73-0P 173999-74-1P 173999-75-2P
173999-76-3P 173999-77-4P 173999-78-5P 173999-79-6P 173999-80-9P
173999-81-0P 173999-82-1P 173999-83-2P 173999-84-3P 173999-85-4P
173999-86-5P 173999-87-6P 173999-88-7P 173999-89-8P 173999-90-1P
173999-91-2P 173999-92-3P 173999-93-4P 173999-94-5P 173999-96-7P
173999-98-9P 173999-99-0P 174000-00-1P 174000-01-2P 174000-02-3P
174000-03-4P 174000-04-5P 174000-05-6P 174000-06-7P 174000-08-9P
174000-09-0P 174000-10-3P 174000-11-4P 174000-12-5P 174000-13-6P
174000-14-7P 174000-15-8P 174000-16-9P 174000-17-0P 174000-18-1P
174000-19-2P 174000-20-5P 174000-21-6P 174000-22-7P 174000-23-8P
174000-24-9P 174000-25-0P 174000-26-1P 174000-27-2P 174000-28-3P
174000-29-4P 174000-30-7P 174000-31-8P 174000-32-9P 174000-33-0P
174000-34-1P 174000-35-2P 174000-37-4P 174000-38-5P 174000-39-6P
174000-40-9P 174000-41-0P 174000-42-1P 174000-43-2P 174000-44-3P
174000-45-4P 174000-46-5P 174000-47-6P 174000-48-7P 174000-50-1P
174000-52-3P 174000-53-4P 174000-54-5P 174000-55-6P 174000-56-7P
174000-57-8P 174000-58-9P 174000-59-0P 174000-60-3P 174000-62-5P
174000-63-6P 174000-64-7P 174000-65-8P 174000-66-9P 174000-67-0P
174000-69-2P 174000-71-6P 174000-72-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzo-fused 5-membered heterocyclic compound 5-HT1 receptor antagonist analgesics for the treatment of migraine headaches)

IT **156492-14-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzo-fused 5-membered heterocyclic compound 5-HT1 receptor antagonist analgesics for the treatment of migraine headaches)

RN 156492-14-7 HCAPLUS
CN 5-Benzofurancarboxylic acid, 3-(cyanomethyl)-, methyl ester (9CI) (CA INDEX NAME)



L60 ANSWER 10 OF 15 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:998201 HCAPLUS
DN 124:175833
ED Entered STN: 22 Dec 1995
TI Preparation of naphthofurans, benzochromenes, and related compounds as **melatonin** receptor ligands.
IN North, Peter Charles; Ladlow, Mark
PA Glaxo Group Ltd., UK
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DT **Patent**
LA English
IC ICM C07D307-92
ICS C07D311-92; A61K031-34; A61K031-35
CC 27-14 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9529173	A1	19951102	WO 1995-EP1415	19950419 <--
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9524464	A1	19951116	AU 1995-24464	19950419 <--
	ZA 9503140	A	19960105	ZA 1995-3140	19950419 <--
	EP 821681	A1	19980204	EP 1995-918557	19950419 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT				
	JP 10502336	T2	19980303	JP 1995-527323	19950419 <--
PRAI	GB 1994-7919		19940421 <--		
	WO 1995-EP1415		19950419 <--		

OS MARPAT 124:175833
GI



I

AB Title compds. [I; R1 = CR3R4(CH2)pNR5COR6; R2 = H, halo, alkyl, OR7, CO2R7; R3-R5 = H, alkyl; R6 = alkyl, cycloalkyl; R7 = H, alkyl; n = 0-2; p = 1-4; q = 1, 2; dotted lines indicate the absence or presence of addnl. bonds], were prepared as **melatonin** agonists/antagonists. Thus, N-[2-(4-fluoronaphtho[2,1-b]furan-9-yl)ethyl]acetamide (preparation given) was hydrogenated in EtOH over Pd/C at room temperature and atmospheric pressure to give N-[2-(4-fluoro-1,2-dihydronaphtho[2,1-b]furan-9-yl)ethyl]acetamide. The latter bound to chick and rabbit retinas with Ki = 0.18 nM and 0.0031 nM, resp.

ST naphthofuran benzochromene **melatonin** receptor ligand prepn

IT 73-31-4, **Melatonin**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(agonists and antagonists; a preparation of naphthofurans, benzochromenes, and related compds. as **melatonin** receptor ligands)

IT 173668-72-9P 173668-73-0P 173668-74-1P 173668-75-2P 173668-76-3P
173668-77-4P 173668-78-5P 173668-80-9P 173668-81-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of naphthofurans, benzochromenes, and related compds. as **melatonin** receptor ligands)

IT 75-36-5, Acetyl chloride 85-41-6, Phthalimide 96-32-2, Methyl bromoacetate 106-96-7, Propargyl bromide 345-08-4 2032-35-1, Bromoacetaldehyde diethyl acetal 4023-34-1, Cyclopropanecarbonyl chloride 121454-72-6 **152302-45-9** 173669-12-0, 4-Chroman-6-ylbutyric acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of naphthofurans, benzochromenes, and related compds. as **melatonin** receptor ligands)

IT 173668-79-6P 173668-82-1P 173668-83-2P 173668-84-3P 173668-85-4P
173668-86-5P 173668-87-6P 173668-88-7P 173668-89-8P 173668-90-1P
173668-91-2P 173668-92-3P, Naphtho[2,1-b]furan-9-ethanol 173668-93-4P
173668-94-5P 173668-95-6P 173668-96-7P 173668-97-8P 173668-98-9P
173668-99-0P 173669-00-6P 173669-01-7P 173669-02-8P 173669-03-9P
173669-04-0P 173669-05-1P 173669-06-2P 173669-07-3P 173669-08-4P
173669-09-5P 173669-10-8P 173669-11-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of naphthofurans, benzochromenes, and related compds. as **melatonin** receptor ligands)

IT **152302-45-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of naphthofurans, benzochromenes, and related compds. as **melatonin** receptor ligands)

RN 152302-45-9 HCAPLUS

CN Acetamide, N-[2-(7-hydroxy-1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)



L60 ANSWER 11 OF 15 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:742950 HCAPLUS
DN 123:169376
ED Entered STN: 18 Aug 1995
TI Preparation of 1-(aminoethyl)naphthalene derivatives having binding affinity for **melatonin** receptors
IN Depreux, Patrick; Hait Mansour, Hamid; **Lesieur, Daniel**; Lefoulon, Francois; **Renard, Pierre**; Adam, Gerard; **Delagrange, Philippe**
PA **Adir et Cie., Fr.**
SO Eur. Pat. Appl., 30 pp.
CODEN: EPXXDW
DT **Patent**
LA French
IC ICM C07C233-31
ICS C07C233-61; C07C233-18; C07C233-60; C07C327-42; C07C327-46; C07C275-24; C07C275-26; A61K031-16; A61K031-17; A61K031-18
CC 25-24 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 63
FAN.CNT 1

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	EP 662471	A2	19950712		EP 1994-402789	19941206	<--
	EP 662471	A3	19950802				
	EP 662471	B1	19980311				
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE						
	FR 2713636	A1	19950616		FR 1993-14630	19931207	<--
	FR 2713636	B1	19960105				
	AU 9480215	A1	19950615		AU 1994-80215	19941205	<--
	AU 677868	B2	19970508				
	CA 2137445	AA	19950608		CA 1994-2137445	19941206	<--
	JP 07224017	A2	19950822		JP 1994-301805	19941206	<--
	US 5591775	A	19970107		US 1994-349914	19941206	<--
	AT 163919	E	19980315		AT 1994-402789	19941206	<--
	ES 2116555	T3	19980716		ES 1994-402789	19941206	<--
	ZA 9409752	A	19950817		ZA 1994-9752	19941207	<--
	US 5552418	A	19960903		US 1995-447886	19950523	<--
PRAI	FR 1993-14630		19931207	<--			
	US 1994-349914		19941206	<--			

OS MARPAT 123:169376
GI



I

AB The title compds. [I; R = H, (un)substituted alkyl, OH, alkoxy, cycloalkoxy, (un)substituted PhO, etc.; R1 = H, alkyl; R2 = C(:X1)R4, C(:X2)NHR5; R4 = H, (un)substituted alkyl, (un)substituted cycloalkyl, (un)substituted alkenyl, (un)substituted alkynyl; R5 = H, alkyl, cycloalkyl, cycloalkylalkyl; X1, X2 = O, S; R3 = (un)substituted alkyl, (un)substituted cycloalkylalkyl, (un)substituted alkenyl, (un)substituted alkynyl, H (only on ring position number 3), Bz, etc.], which have affinity for **melatonin** receptors (no data), useful for the treatment of pain (no data), depression (no data), obesity (no data), etc., are prepared Thus, N-[2-(7-methoxynaphth-1-yl)ethyl]acetamide was acylated with BzCl in the presence of AlCl3, producing N-[2-(7-methoxy-3-benzoylnaphth-1-yl)ethyl]acetamide, m.p. 92-95°.

ST aminoethylnaphthalene prepn **melatonin** receptor binding

IT Analgesics
Antidepressants
Antiobesity agents
Appetite depressants
Cardiovascular agents
Hypnotics and Sedatives
(1-(aminoethyl)naphthalene derivs.)

IT **Receptors**
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**melatonin**, 1-(aminoethyl)naphthalene derivs. with binding affinity for)

IT 75-36-5, Acetyl chloride 79-03-8, Propanoyl chloride 98-88-4, Benzoyl chloride 108-88-3, Toluene, reactions 1310-73-2, Sodium hydroxide, reactions 4023-34-1, Cyclopropanecarbonyl chloride 7439-97-6, Mercury, reactions 7440-66-6, Zinc, reactions 7647-01-0, Hydrochloric acid, reactions **138112-76-2**, N-[2-(7-Methoxynaphth-1-yl)ethyl]acetamide 138113-03-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 1-(aminoethyl)naphthalene derivs. having binding affinity for **melatonin** receptors)

IT 166526-93-8P 166526-94-9P 166526-96-1P 166526-98-3P 166526-99-4P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 1-(aminoethyl)naphthalene derivs. having binding affinity for **melatonin** receptors)

IT 166526-95-0P 166526-97-2P 166527-00-0P 166527-01-1P 166527-02-2P 166527-03-3P 166527-04-4P 166527-05-5P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-(aminoethyl)naphthalene derivs. having binding affinity for **melatonin** receptors)

IT 166526-95-0P 166526-97-2P 166527-00-0P 166527-01-1P 166527-02-2P 166527-03-3P 166527-04-4P 166527-05-5P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-(aminoethyl)naphthalene derivs. having binding affinity for **melatonin** receptors)

IT **138112-76-2**, N-[2-(7-Methoxynaphth-1-yl)ethyl]acetamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 1-(aminoethyl)naphthalene derivs. having binding affinity for **melatonin** receptors)

RN 138112-76-2 HCAPLUS

CN Acetamide, N-[2-(7-methoxy-1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)



L60 ANSWER 12 OF 15 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:106566 HCAPLUS
DN 120:106566
ED Entered STN: 05 Mar 1994
TI Preparation of naphthylalkylamines as **melatonin** antagonists
IN Yous, Said; **Lesieur, Daniel**; Depreux, Patrick; Guardiola-Lemaitre, Beatrice; Adam, Gerard; **Renard, Pierre**; Caignard, Daniel Henri
PA **ADIR et Co., Fr.**
SO Eur. Pat. Appl., 25 pp.
CODEN: EPXXDW
DT **Patent**
LA French
IC ICM C07C233-58
ICS A61K031-16; C07C233-60; C07D207-267; C07C275-24; C07C233-05; A61K031-17; A61K031-40
CC 25-24 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1
FAN.CNT 1

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	EP 562956	A1	19930929		EP 1993-400757	19930324	<--
	EP 562956	B1	19950927				
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE						
	FR 2689124	A1	19931001		FR 1992-3700	19920327	<--
	US 5420158	A	19950530		US 1993-35936	19930323	<--
	AT 128458	E	19951015		AT 1993-400757	19930324	<--
	ES 2081187	T3	19960216		ES 1993-400757	19930324	<--
	CA 2092794	AA	19930928		CA 1993-2092794	19930326	<--
	CA 2092794	C	19990323				
	AU 9335445	A1	19930930		AU 1993-35445	19930326	<--
	AU 657400	B2	19950309				
	ZA 9302168	A	19931108		ZA 1993-2168	19930326	<--
	JP 06049011	A2	19940222		JP 1993-105844	19930326	<--
	JP 07049404	B4	19950531				
	US 5616614	A	19970401		US 1995-377812	19950125	<--
PRAI	FR 1992-3700		19920327	<--			
	US 1993-35936		19930323	<--			

OS MARPAT 120:106566
GI



I II

AB Title compds. [I; R = H, OR4; R1 = H, CO2R5; R2 = H, (substituted) alkyl; R3 = CO(CH2)nR6, C(:X)NH(CH2)mR7; R4 = H, (cyclo)alkyl, (di)phenyl(alkyl),

etc.; R5 = H, alkyl; R6 = H, (cyclo)alkyl, alkenyl, heterocyclyl, etc.; R7 = (cyclo)alkyl, Ph, etc.; X = O, S; m, n = 0-3] were prepared Thus, cyclobutanecarbonyl chloride was amidated by 2-(1-naphthyl)ethylamine to give title compound II, which gave significant (sic) antagonism of **melatonin**-induced pigment aggregation in amphibian dermal melanophores at 10-7 M in vitro.

ST naphthylalkylamine prepn **melatonin** antagonist

IT Immunomodulators
Nervous system agents
(naphthylalkylamines)

IT Endocrine system
(disease, treatment of, naphthylalkylamines for)

IT **Receptors**
RL: RCT (Reactant); RACT (Reactant or reagent)
(**melatonin**, antagonists of, naphthylalkylamines as)

IT 73-31-4, **Melatonin**
RL: RCT (Reactant); RACT (Reactant or reagent)
(antagonists of, naphthylalkylamines as)

IT 144705-51-1P 152302-36-8P 152302-37-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of **melatonin** antagonists)

IT 144489-33-8P 144489-34-9P 144489-35-0P 148057-31-2P 152302-33-5P 152302-34-6P 152302-35-7P 152302-38-0P 152302-39-1P 152302-40-4P 152302-41-5P 152302-42-6P 152302-43-7P 152302-44-8P
152302-45-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as **melatonin** antagonist)

IT 100-39-0, Benzyl bromide 132-75-2, 2-(1-Naphthyl)acetonitrile 776-74-9, Diphenylmethyl bromide 942-05-2, 2-(1-Naphthyl)ethylamine hydrochloride 1521-51-3, 3-Bromocyclohexene 4023-34-1, Cyclopropanecarbonyl chloride 5006-22-4, Cyclobutanecarbonyl chloride 138113-08-3, 2-(7-Methoxy-1-naphthyl)acetonitrile 139525-77-2, 2-(7-Methoxy-1-naphthyl)ethylamine hydrochloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of **melatonin** antagonist)

IT **152302-45-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as **melatonin** antagonist)

RN 152302-45-9 HCAPLUS

CN Acetamide, N-[2-(7-hydroxy-1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)



L60 ANSWER 13 OF 15 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1992:20792 HCAPLUS

DN 116:20792

ED Entered STN: 24 Jan 1992

TI Preparation of N-[(alkoxynaphthyl)ethyl]carboxamides as nervous system agents

IN Andrieux, Jean; Houssin, Raymond; Yous, Said; Guardiola, Beatrice; **Lesieur, Daniel**

PA **ADIR et Cie., Fr.**

SO Eur. Pat. Appl., 37 pp.
CODEN: EPXXDW

DT **Patent**
LA French
IC ICM C07C233-17
ICS C07C233-73; C07C233-60; C07C233-22; C07C237-08; C07D207-12; C07D295-15
CC 25-24 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1
FAN.CNT 1

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	EP 447285	A1	19910918		EP 1991-400526	19910227	<--
	EP 447285	B1	19930512				
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE						
	FR 2658818	A1	19910830		FR 1990-2393	19900227	<--
	FR 2658818	B1	19931231				
	CA 2036876	AA	19910828		CA 1991-2036876	19910222	<--
	CA 2036876	C	19980818				
	AU 9171375	A1	19910829		AU 1991-71375	19910226	<--
	AU 634350	B2	19930218				
	ZA 9101403	A	19911127		ZA 1991-1403	19910226	<--
	US 5194614	A	19930316		US 1991-661425	19910226	<--
	AT 89263	E	19930515		AT 1991-400526	19910227	<--
	ES 2059069	T3	19941101		ES 1991-400526	19910227	<--
	JP 07048331	A2	19950221		JP 1991-33192	19910227	<--
	US 5225442	A	19930706		US 1992-816466	19920103	<--
	US 5318994	A	19940607		US 1992-970578	19921103	<--
PRAI	FR 1990-2393		19900227	<--			
	US 1991-661425		19910226	<--			
	EP 1991-400526		19910227	<--			
	US 1992-816466		19920103	<--			

OS MARPAT 116:20792
GI



I



II

AB Title compds. [I; R = alkyl; R1 = H, alkyl; R2 = H, (halo)alkyl, (halo)cycloalkyl, aralkyl, (hetero)aryl, etc.; R1R2 = atoms to complete a ring], having high affinity for **melatonin** receptors, were prepared Thus, 7-methoxy-1-tetralone was converted in 7 steps to 2-(7-methoxynaphth-1-yl)ethylamine which was condensed with PhCH2COCl to give title compound II. Certain I had K.d = 5.5 + 10-13 (no units given) for binding at **melatonin** receptors, vs. 6.3 + 10-11 for **melatonin** itself.
ST alkoxynaphthylethylcarboxamide prepn nervous system agent
IT Ovulation
(inhibitors of, N-[(alkoxynaphthyl)ethyl]carboxamides as)
IT Ischemia
(treatment of, N-[(alkoxynaphthyl)ethyl]carboxamides for)
IT Analgesics

Anticonvulsants and Antiepileptics
Anxiolytics
Immunostimulants
Neoplasm inhibitors
Nervous system agents
(N-[(alkoxynaphthyl)ethyl]carboxamides)

IT 6836-21-1P 6836-22-2P 138113-06-1P 138113-07-2P 138113-08-3P 138113-09-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of nervous system agents)

IT **138112-76-2P 138112-77-3P** 138112-78-4P 138112-79-5P
138112-80-8P 138112-81-9P 138112-82-0P 138112-83-1P 138112-84-2P
138112-85-3P 138112-86-4P 138112-87-5P 138112-88-6P 138112-89-7P
138112-90-0P 138112-91-1P 138112-92-2P 138112-93-3P 138112-94-4P
138112-95-5P 138112-96-6P 138112-97-7P 138112-98-8P 138112-99-9P
138113-00-5P 138113-01-6P 138113-02-7P 138113-03-8P 138113-04-9P
138113-05-0P 138113-12-9P 138113-13-0P 138113-14-1P 138136-25-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as nervous system agent)

IT 79-03-8, Propionyl chloride 79-30-1, Isobutyryl chloride 98-88-4, Benzoyl chloride 100-46-9, Benzyl amine, reactions 103-80-0, Phenylacetyl chloride 105-36-2, Ethyl bromoacetate 110-91-8, Morpholine, reactions 141-75-3, Butyryl chloride 403-43-0, p-Fluorobenzoyl chloride 638-29-9, Pentanoyl chloride 874-60-2, p-Toluoyl chloride 2251-65-2, 3-Trifluoromethylbenzoyl chloride 2719-27-9, Cyclohexanecarbonyl chloride 2905-62-6, 3,5-Dichlorobenzoyl chloride 4023-34-1, Cyclopropanecarbonyl chloride 4635-59-0, 4-Chlorobutyryl chloride 5011-34-7 5271-67-0, 2-Thiophenecarbonyl chloride 6836-19-7, 7-Methoxy-1-tetralone 14254-57-0, 4-Pyridinecarbonyl chloride 22118-09-8, Bromoacetyl chloride 54745-92-5, 2-Quinoxalinecarbonyl chloride 56460-32-3, 1H-Imidazole-4-carbonyl chloride 58881-45-1, 1H-Indole-2-carbonyl chloride 59776-88-4 138113-10-7 138113-11-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of nervous system agents)

IT **138112-76-2P 138112-77-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as nervous system agent)

RN 138112-76-2 HCAPLUS
CN Acetamide, N-[2-(7-methoxy-1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 138112-77-3 HCAPLUS
CN Benzeneacetamide, N-[2-(7-methoxy-1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)



L60 ANSWER 14 OF 15 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1979:203856 HCAPLUS
DN 90:203856
ED Entered STN: 12 May 1984
TI 5-Substituted-2-phenylbenzo[b]thiophene-3-alkylamines and related compounds
IN Kukla, Michael J.
PA G.D. Searle and Co., USA
SO U.S., 13 pp.
CODEN: USXXAM
DT **Patent**
LA English
IC C07D333-58
NCL 544376000
CC 27-8 (Heterocyclic Compounds (One Hetero Atom))
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4137414	A	19790130	US 1977-836868	19770926 <--
PRAI	US 1977-836868		19770926 <--		

GI



I

AB The title compds. I (R, R1 = H, C1-8 alkyl, RR1N = pyrrolidinyl, piperazinyl, C1-4 alkylpyrrolidinyl, C1-4 alkyl- and hydroxyalkylpiperazinyl; R2 = H, C1-4 alkyl; R3 = H, halo, C1-4 alkyl, C1-4 alkoxy; n = 1-4) were prepared Thus, 5-chloro-2-phenylbenzo[b]thiophene-3-acetonitrile, prepared from p-ClC6H4SH and PhCHBrCOMe in 4 steps, was reduced with NaBH4 to give I (R = R1 = R3 = H, R2 = Cl, n = 2). I possessed neuroleptic activity comparable to clozapine and chloropromazine and I.2HCl (RR1N = 4-methyl-1-piperazinyl, R2 = Cl, n = 2) was bactericidal against Escherichia coli at 10 μg/mL.
ST benzothiophenealkylamine; neuroleptic benzothiophenealkylamine; bactericide benzothiophenealkylamine; redn benzothiopheneacetonitrile
IT Bactericides, Disinfectants and Antiseptics
Tranquilizers and Neuroleptics
(phenylbenzothiophenealkylamines)
IT **65712-06-3P** 65712-18-7P 70230-99-8P 70231-01-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological

study); PREP (Preparation)
(preparation and bactericidal activity of)

IT **51828-63-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and bromination of)

IT 51828-62-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of, benzothiophene derivative from)

IT 65712-15-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis-decarboxylation of)

IT 65712-08-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and methylation of)

IT 65712-19-8P 65712-20-1P 65712-21-2P 65712-22-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and neuroleptic activity of)

IT 65712-12-1P **65712-14-3P** 65712-17-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

IT **51828-64-9P** 65712-13-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and substitution reactions of)

IT 65712-11-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and tosylation of)

IT 65712-03-0P 65712-04-1P 65712-05-2P 65712-07-4P 65712-09-6P
65712-10-9P 65712-16-5P 65712-17-6P 70230-98-7P 70231-00-4P
70231-02-6P 70231-03-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

IT 106-54-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with bromophenylacetone)

IT 74-89-5, reactions 109-01-3 109-89-7, reactions 124-40-3, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with chlorophenylbenzylthiopheneethyl tosylate)

IT 23022-83-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with chlorothiophenol)

IT 70231-04-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with dimethylamine)

IT 70231-05-9 70231-06-0 70255-19-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(reduction of)

IT **65712-06-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal activity of)

RN 65712-06-3 HCAPLUS
CN Benzo[b]thiophene-3-ethanamine, 5-chloro-2-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **51828-63-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and bromination of)
RN 51828-63-8 HCAPLUS
CN Benzo[b]thiophene, 5-chloro-3-methyl-2-phenyl- (9CI) (CA INDEX NAME)



IT **65712-14-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)
RN 65712-14-3 HCAPLUS
CN Benzo[b]thiophene-3-acetonitrile, 5-chloro-2-phenyl- (9CI) (CA INDEX NAME)



IT **51828-64-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and substitution reactions of)
RN 51828-64-9 HCAPLUS
CN Benzo[b]thiophene, 3-(bromomethyl)-5-chloro-2-phenyl- (9CI) (CA INDEX NAME)



L60 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1969:491283 HCAPLUS

DN 71:91283
ED Entered STN: 12 May 1984
TI Antibacterial substituted benzo[b]thiophenes
IN James, John W.; Chapman, Norman B.; Clarke, Kenneth
PA Aspro-Nicholas Ltd.
SO Ger. Offen., 64 pp.
CODEN: GWXXBX
DT **Patent**
LA German
IC C07D; A61K
CC 27 (Heterocyclic Compounds (One Hetero Atom))
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 1813836		19690710		<--
GB 1229580			GB	
PRAI GB		19671215 <--		

GI For diagram(s), see printed CA Issue.
AB Title compds. are prepared Thus, 100 ml. aqueous 20% NaOH is added at 0° to 0.04 mole aqueous solution of 2-[5-chloro-3-benzo[b]thien-2-yl]-ethylamine-HCl, and 25 ml. Ac2O added with shaking and cooling to form N-acetyl-2-[5-chloro-3-benzo[b]thien-2-yl]ethylamine (I), m. 131-2° (C6H6). The following compds. were prepared (m.p. given): N-acetyl-2-[3-benzo[b]thienyl]ethylamine, 67-8°; N-(3,4-dimethoxyphenacetyl)-2-[3-benzo[b]thienyl]-ethylamine, 111-12°; N-(3,4-dimethoxyphenacetyl)-2-[5-chloro-3-benzo[b]thienyl]ethylamine, 127-8°; 1-methyl-3,4-dihydrobenzo[b]thieno[2,3-c]pyridine, 75-6°; 6-chloro-1-methyl-3,4-dihydrobenzo[b]thieno[2,3-c]pyridine, 147-8°; N-(3,4-dimethoxyphenacetyl-3,4-dihydrobenzo[b]thieno[2,3-c]pyridine, 147-8°; 1-methyl-1,2,3,4-tetrahydrobenzo[b]thieno[2,3-c]pyridine, 256-8° (decomposition); 6-chloro-1-methyl-1,2,3,4-tetrahydrobenzo[b]-thieno[2,3-c]pyridine-HCl, 313-15° (decomposition); 1-methylbenzo[b]thieno[2,3-c]pyridine, 104-6°; N-[2-[5-chloro-3-benzo-[b]thienyl]ethyl]urea, 195-6°. N-[5-chloro-3-benzo[b]thienylmethyl]urea, 204-5°; N-[3-benzo[b]thienylmethyl]urea, 194-5°; N-[5-chloro-2-benzo[b]thienylmethyl]urea, 194-5°; N-[2-[5-chloro-2-benzo[b]thienyl]ethyl]urea, 144-5°; N-[2-[5-bromo-2-benzo[b]thienyl]ethyl]urea, 140-1°; N-[5-bromo-2-benzo[b]thienylmethyl)urea, 189-90°; N-[3-methyl-5-benzo[b]thienylmethyl]urea, 199-200°; N-[2-[3-benzo[b]thienyl]ethyl]urea, 172-3°. N-[2-[5-methoxy-3-benzo[b]thienyl]ethyl]urea, 185-6°; N-[2-[5-methoxy-2-benzo[b]thienyl]ethyl]urea, 168-70°; N-[5-bromo-3-benzo[b]thienylmethyl]urea, 211-13°; N-[5-fluoro-2-benzo[b]thienylmethyl]urea, 191-2°; N-[5-fluoro-2-benzo[b]thienylmethyl]-N-methylurea, 164-6°; N-[5-iodo-2-benzo[b]thienylmethyl]urea, 281-3°; N-[5-methyl-2-benzo[b]-thienylmethyl]urea, 206-8°; 1-[5-chloro-3-benzo[b]thienylmethyl]guanidine-HI, 182-3°; 1-[5-chloro-3-benzo[b]thienylmethyl]guanidine-HCl, 174-5°. 1-[3-benzo[b]thienylmethyl]-guanidine-HI, 156-7° (HCl salt m. 184-5°); 1-[2-[3-benzo[b]-thienyl]ethyl]guanidine-HI, 155-6° (HCl salt, m. 191-2°); 1-[2-[5-chloro-3-benzo[b]thienyl]ethyl]guanidine-HI, 195-6°; 1-[5-bromo-2-benzo[b]thienylmethyl]guanidine-HI, 210-11°; 1-[5-bromo-3-benzo[b]thienylmethyl]guanidine-HCl, 211-13°; 1-[5-chloro-3-benzo[b]thienylmethyl]-3-methylguanidine-HCl, 200-1°; 1-[5-chloro-3-benzo[b]thienylmethyl]-3-phenylguanidine-HCl, 165-6°. 1-[5-chloro-3-benzo[b]thienylmethyl]-2,3-dimethylguanidine-HCl, 180-1°; 1-[5-chloro-3-benzo[b]thienylmethyl]-3,3-dimethylguanidine-HCl, 238-9°; 1-[2-[5-chloro-3-benzo[b]thienyl]ethyl]-3-

methylguanidine-HCl, 139-40°; 1-[3-methyl-5-benzo[b]thienylmethyl]guanidine-HI, 186-7°; 1-[2-[5-methoxy-3-benzo[b]thienyl]ethyl]guanidine-HI, 177-9°; 1-[2-[5-chloro-3-benzo[b]thienyl]ethyl]-3-phenylguanidine-HCl, 164-5°; 1-[2-[5-chloro-3-benzo[b]thienyl]ethyl]-2,3-dimethylguanidine-HCl, 230-1°. 1-[2-[5-chloro-3-benzo[b]thienyl]ethyl]-3,3-dimethylguanidine-HCl, 217-18°; 1-[5-bromo-3-benzo[b]thienylmethyl]-3-methylguanidine-HCl, 221-2°; 1-[5-bromo-3-benzo-[b]thienylmethyl]-3-phenylguanidine-HCl, 160-4°; 1-[5-bromo-3-benzo[b]thienylmethyl]-3-carboxyethylguanidine-HCl, 182-4°; 1-[5-bromo-2-benzo[b]thienylmethyl]-3-carboxyethylguanidine-HCl, 190-2°; 1-[5-chloro-3-benzo[b]thienylmethyl]-3-carboxy-ethylguanidine-HCl, 187-9°; 5-methyl-3-benzo[b]thienyl-methylamidoxime (II), 110-12°; 3-benzo[b]thienylmethylamid-oxime, 128-9°. 5-chloro-3-benzo[b]thienylmethylamidoxime, 160-1°; 5-bromo-3-benzo[b]thienylmethylamidoxime, 185-6°; O-Et [5-chloro-3-benzo[b]thienyl]acetamidate-HCl, 206-8°; (decomposition); O-Et [3-benzo[b]thienyl]acetamidate-HCl, 98-100° (decomposition); O-Et [5-methyl-3-benzo[b]thienyl]acetamidate-HCl, 105-7° (decomposition); O-Et [5-bromo-3-benzo[b]thienyl]-acetamidate-HCl, 230-2° (decomposition); [5-bromo-3-benzo[b]thienyl]acetamidine-HCl, 322-3°; [3-benzo[b]thienyl]acetamidine-HCl, 166-7°; [5-methyl-3-benzo[b]thienyl]acetamidine-HCl, 256-7°; [5-chloro-3-benzo[b]thienylacetamidine-HCl, 303-4°. N-methyl[5-bromo-3-benzo[b]thienyl]acetamide, 168-70°; N-methyl[3-benzo[b]thienyl]acetamide, 120-2°; N,N-dimethyl[5-methyl-3-benzo[b]thienyl]acetamide, 82-4°; N-methyl[5-methyl-3-benzo[b]thienyl]acetamide, 115-16°; N-methyl[5-chloro-3-benzo[b]thienyl]acetamide, 150-1°; N,N-dimethyl[5-chloro-3-benzo[b]thienyl]acetamide, 88-90°; N,N-dimethyl[5-bromo-3-benzo[b]thienyl]acetamide, 107-8°. 7-bromo-2,3-dihydro-2,2-tetramethylene-1H[1]-benzo[b]thieno[2,3-c]pyrrolium bromide, 255-6°; 7-chloro-2-(2-hydroxyethyl)-2,3-dihydro-1H[1]-benzo-[b]thieno[2,3-c]pyrrole-HCl, 232-3° (2-chloroethyl analog-HCl m. 217-19°); 7-bromo-2-tert-butyl-2,3-dihydro-1H[1]benzo[b]-thieno[2,3-c]pyrrole-HCl, 248-9°; 7-chloro-2-cyclohexyl-2,3-dihydro-1H[1]-benzo[b]thieno[2,3-c]pyrrole-HCl, 254-5°; 7-bromo-2-benzyl-2,3-dihydro-1H[1]-benzo[b]thieno[2,3-c]pyrrole-HBr, 234°; 7-chloro-2,2-dimethyl-2,3-dihydro-1H-[1]-benzo[b]-thieno[2,3-c]pyrrolium bromide, 225-6°; 7-bromo-2,2-dimethyl-2,3-dihydro-1H[1]-benzo[b]thieno[2,3-c]pyrrolium bromide, 229-30°. 7-chloro-2,2-diethyl-2,3-dihydro-1H[1]-benzo[b]thieno-[2,3-c]pyrrolium bromide, 207-8°; 7-bromo-2,2-diethyl-2,3-dihydro-1H[1]-benzo[b]thieno[2,3-c]pyrrolium bromide, 215-16°; 7-chloro-2,2-dibenzyl-2,3-dihydro-1H[1]benzo[b]-thieno[2,3-c]-pyrrolium bromide, 180-4°; 7-bromo-2,2-dibenzyl-2,3-dihydro-1H[1]-benzo[b]thieno[2,3-c]pyrrolium bromide, 174-5°; 7-chloro-2,2-tetramethylene-2,3-dihydro-1H[1]benzo[b]thieno-[2,3-c]pyrrolium bromide, 256-7°; 7-chloro-2,2-pentamethylene-2,3-dihydro-1H[1]-benzo[b]-[b]thieno[2,3-c]pyrrolium bromide, 250-1°. 7-bromo-2,2-pentamethylene-2,3-dihydro-1H[1]-benzo[b]-thieno[2,3-c]pyrrolium bromide, 244-5°; 7-chloro-2,2-anhydrobis(2-hydroxyethyl)-2,3-dihydro-1H[1]-benzo[b]thieno[2,3-c]-pyrrolium bromide, 220-1°; 7-bromo-2,2-anhydrobis(2-hydroxyethyl)-2,3-dihydro-1H[1]-benzo[b]thieno[2,3-c]pyrrolium bromide, 217-18°; 7-chloro-2-methyl-2-(2-hydroxyethyl)-2,3-dihydro-1H[1]-benzo[b]thieno[2,3-c]pyrrolium bromide, 209-10°; 7-bromo-2-methyl-2-(2-hydroxyethyl)-2,3-dihydro-1H[1]-benzo-[b]thieno[2,3-c]pyrrolium bromide, 208-9°; 7-chloro-2-ethyl-2-(2-hydroxyethyl)-2,3-dihydro-1H[1]-benzo[b]thieno[2,3-c]pyrrolium bromide, 203-4°. 7-bromo-2-ethyl-2-(2-hydroxyethyl)-2,3-dihydro-1H[1]-benzo[b]thieno[2,3-c]pyrrolium bromide, 198-9°; 7-chloro-2-benzyl-2-(2-hydroxyethyl)-2,3-dihydro-1H[1]-benzo[b]thieno[2,3-c]pyrrolium bromide, 147-8°; 1-[5-chloro-3-

benzo[b]thienylmethyl]biguanide-HCl, 229-30°; 5-chloro-2-morpholinomethylbenzo[b]thiophene-HCl, 239-40°; 5-chloro-2-pyrrolidonomethylbenzo[b]thiophene-HCl, 202-3°; 5-chloro-2-piperidinomethylbenzo[b]thiophene-HCl, 218-19°; 5-bromo-2-piperidinomethylbenzo[b]thiophene-HCl, 203-4°; 5-bromo-2-morpholinomethylbenzo[b]thiophene-HCl, 246-7°; and 5-bromo-2-pyrrolidinomethylbenzo[b]thiophene-HCl, 208-9°.

ST antibacterial benzothiophenes; benzothiophenes antibacterial; thiophenes benzo; amines benzothienyl; guanidines benzothienyl; ureas benzothienyl; morpholines; pyridines; pyrroles

IT Bactericides
(benzothiophene derivs.)

IT Benzo[b]thiophene, amide derivs.
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

IT 16865-89-7P 16865-90-0P 16865-91-1P 16865-92-2P 16865-93-3P
16865-94-4P 16865-95-5P 16865-96-6P 16865-97-7P 16865-98-8P
16865-99-9P 16866-00-5P 16866-02-7P 16866-03-8P 16866-04-9P
16866-07-2P 16866-08-3P 16866-19-6P 16866-20-9P 16866-21-0P
16866-22-1P 16866-23-2P 16877-12-6P 16877-13-7P 16877-14-8P
16899-22-2P 16899-24-4P 18724-52-2P 19985-66-1P 22963-97-9P
22963-98-0P 23799-70-4P 23799-71-5P 23799-72-6P 23799-73-7P
23799-74-8P 23799-90-8P 23799-91-9P 23799-92-0P 23799-93-1P
23799-94-2P 23799-95-3P 23799-96-4P 23799-97-5P 23799-98-6P
23805-99-4P 23806-00-0P 23806-01-1P 23806-02-2P 23806-03-3P
23842-78-6P 23842-80-0P **23962-24-5P** 23962-25-6P
23962-26-7P 23962-27-8P 23962-28-9P 23962-29-0P 23962-30-3P
23962-31-4P 23962-32-5P 23962-41-6P 23962-42-7P 23962-43-8P
23962-44-9P 23962-45-0P 23962-46-1P 23962-47-2P 23962-48-3P
23962-58-5P 23962-59-6P 23962-60-9P 23962-61-0P 23962-62-1P
23962-63-2P 23962-64-3P 23962-65-4P 23962-66-5P 23962-67-6P
23962-68-7P 23962-69-8P 23962-70-1P 23962-71-2P 24035-73-2P
24035-74-3P 24035-75-4P 24035-76-5P 24035-77-6P 24035-78-7P
24035-79-8P 24035-80-1P 24035-81-2P 24035-82-3P 24035-83-4P
24035-84-5P 24067-56-9P 24067-57-0P 24067-58-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

IT **23962-24-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 23962-24-5 HCAPLUS

CN Acetamide, N-[2-(5-chlorobenzo[b]thien-3-yl)ethyl]- (8CI, 9CI) (CA INDEX NAME)



=> => fil reg
FILE 'REGISTRY' ENTERED AT 13:04:53 ON 11 MAR 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 MAR 2004 HIGHEST RN 661450-61-9
DICTIONARY FILE UPDATES: 10 MAR 2004 HIGHEST RN 661450-61-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d scan l48

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Urea, N-methyl-N'-[2-[7-(methylthio)-1-naphthalenyl]ethyl]- (9CI)
MF **C15 H18 N2 O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):50

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[3-[2-(acetylamino)ethyl]-5-benzofuranyl]-2,2,2-trifluoro- (9CI)
MF **C14 H13 F3 N2 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Heptanamide, N-[2-[7-[(phenylmethyl)thio]-1-naphthalenyl]ethyl]- (9CI)
MF **C26 H31 N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, N-[2-[5-(acetylamino)benzo[b]thien-3-yl]ethyl]- (9CI)
MF **C19 H18 N2 O2 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[[8,9-dihydro-2-(phenylmethyl)-7H-thieno[3,2-f][1]benzothiopyran-1-yl]methyl]- (9CI)
MF **C21 H21 N O S2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Cyclopropanecarboxamide, N-[2-[5-[(methylamino)sulfonyl]-3-benzofuranyl]ethyl]- (9CI)
MF **C15 H18 N2 O4 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Cyclopropanecarboxamide, N-[2-(5-chlorobenzo[b]thien-3-yl)ethyl]- (9CI)
MF **C14 H14 Cl N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Carbamic acid, [3-[2-(acetylamino)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-, methyl ester (9CI)
MF **C13 H16 N4 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-(5-bromo-2-phenylbenzo[b]thien-3-yl)ethyl]- (9CI)
MF **C18 H16 Br N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzeneacetamide, N-[2-(7-formyl-1-naphthalenyl)ethyl]- (9CI)
MF **C21 H19 N O2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzeneacetamide, N-[2-(7-methoxy-1-naphthalenyl)ethyl]- (9CI)
MF **C21 H21 N O2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-[3-benzoyl-7-(methylthio)-1-naphthalenyl]ethyl]- (9CI)
MF **C22 H21 N O2 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Carbamic acid, [3-[2-[(cyclopropylcarbonyl)amino]ethyl]-5-benzofuranyl]-, methyl ester (9CI)
MF **C16 H18 N2 O4**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1-Naphthaleneacetamide, 7-(cyclopentylthio)-N-methyl- (9CI)
MF **C18 H21 N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzeneacetamide, N-[2-[7-[(1-oxobutyl)amino]-1-naphthalenyl]ethyl]- (9CI)
MF **C24 H26 N2 O2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[3-(7-methyl-7H-thiopyrano[3,2-e]benzofuran-1-yl)propyl]-
(9CI)
MF **C17 H19 N O2 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-[5-[(methylamino)sulfonyl]-2-(phenylmethyl)benzo[b]thien-3-yl]ethyl]- (9CI)
MF **C20 H22 N2 O3 S2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-(5-bromobenzo[b]thien-3-yl)ethyl]- (9CI)
MF **C12 H12 Br N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Carbamic acid, [3-[2-[(2-furanylcarbonyl)amino]ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-, methyl ester (9CI)
MF **C16 H16 N4 O4**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2-Propenamide, N-[2-(5-chlorobenzo[b]thien-3-yl)ethyl]-3-phenyl- (9CI)
MF **C19 H16 Cl N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2-Naphthalenecarboxylic acid, 8-[2-[(phenylacetyl)amino]ethyl]- (9CI)
MF **C21 H19 N O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-(7-hydroxy-1-naphthalenyl)ethyl]- (9CI)
MF **C14 H15 N O2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-[7-(methylthio)-3-(phenylmethyl)-1-naphthalenyl]ethyl]-
(9CI)
MF **C22 H23 N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Carbamic acid, [3-[2-(acetylamino)ethyl]-5-benzofuranyl]-, 1,1-dimethylethyl ester (9CI)
MF **C17 H22 N2 O4**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1-Naphthaleneacetamide, N-cyclohexyl-7-(cyclopentylthio)- (9CI)
MF **C23 H29 N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Cyclohexanecarboxamide, N-[8-[2-[(bromoacetyl)amino]ethyl]-2-naphthalenyl]- (9CI)
MF **C21 H25 Br N2 O2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-[7-amino-3-(cyclopropylmethyl)-1-naphthalenyl]ethyl]- (9CI)
MF **C18 H22 N2 O**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Cyclopropanecarboxamide, N-[2-[5-[[(1-methylethyl)amino]sulfonyl]benzo[b]thien-3-yl]ethyl]- (9CI)
MF **C17 H22 N2 O3 S2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-(5-bromobenzo[b]thien-3-yl)ethyl]-2,2,2-trifluoro- (9CI)
MF **C12 H9 Br F3 N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Carbamic acid, [3-[2-(benzoylamino)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-, methyl ester (9CI)
MF **C18 H18 N4 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2-Propenamide, N-[2-(5-bromobenzo[b]thien-3-yl)ethyl]-3-phenyl- (9CI)
MF **C19 H16 Br N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2-Naphthalenecarbonyl chloride, 8-[2-[(phenylacetyl)amino]ethyl]- (9CI)
MF **C21 H18 Cl N O2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5-Benzofurancarboxylic acid, 3-(cyanomethyl)-, methyl ester (9CI)
MF **C12 H9 N O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-[7-(ethylthio)-1-naphthalenyl]ethyl]- (9CI)
MF **C16 H19 N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-[7-(aminosulfonyl)-1-naphthalenyl]ethyl]- (9CI)
MF **C14 H16 N2 O3 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-[3-phenyl-7-(2-propenylthio)-1-naphthalenyl]ethyl]- (9CI)
MF **C23 H23 N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[8-[2-(acetylamino)ethyl]-2-naphthalenyl]- (9CI)
MF **C16 H18 N2 O2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzeneacetamide, N-[2-[7-(diethylamino)-1-naphthalenyl]ethyl]- (9CI)
MF **C24 H28 N2 O**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-[5-[(methylamino)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]ethyl]- (9CI)
MF **C12 H16 N4 O3 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Butanamide, N-[2-(5-bromobenzo[b]thien-3-yl)ethyl]- (9CI)
MF **C14 H16 Br N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Carbamic acid, [3-[2-[(cyclopropylcarbonyl)amino]ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-, methyl ester (9CI)
MF **C15 H18 N4 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3-Butenamide, N-[2-(5-chlorobenzo[b]thien-3-yl)ethyl]-4-phenyl- (9CI)
MF **C20 H18 Cl N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzeneacetamide, N-[2-(7-amino-1-naphthalenyl)ethyl]- (9CI)
MF **C20 H20 N2 O**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzeneacetamide, N-[2-(7-hydroxy-1-naphthalenyl)ethyl]- (9CI)
MF **C20 H19 N O2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-[7-(propylthio)-1-naphthalenyl]ethyl]- (9CI)
MF **C17 H21 N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-[7-[(methylamino)sulfonyl]-1-naphthalenyl]ethyl]- (9CI)
MF **C15 H18 N2 O3 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-[3-phenyl-7-[(phenylmethyl)thio]-1-naphthalenyl]ethyl]-
(9CI)
MF **C27 H25 N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2-Naphthalenecarboxamide, N-ethyl-8-[2-[(phenylacetyl)amino]ethyl]- (9CI)
MF **C23 H24 N2 O2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-[7-(hexylamino)-1,2,3,4-tetrahydro-1-naphthalenyl]ethyl]- (9CI)
MF **C20 H32 N2 O**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Cyclopropanecarboxamide, N-[2-[5-[(methylamino)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]ethyl]- (9CI)
MF **C14 H18 N4 O3 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Urea, N-[2-(5-bromobenzo[b]thien-3-yl)ethyl]-N'-methyl- (9CI)
MF **C12 H13 Br N2 O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):50

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Carbamic acid, [8-[2-[(bromoacetyl)amino]ethyl]-2-naphthalenyl]-, ethyl ester (9CI)
MF **C17 H19 Br N2 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3-Butenamide, N-[2-(5-bromobenzo[b]thien-3-yl)ethyl]-4-phenyl- (9CI)
MF **C20 H18 Br N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5-Benzofurancarboxylic acid, 3-(2-aminoethyl)-, methyl ester, hydrochloride (9CI)
MF **C12 H13 N O3 . Cl H**



● HCl

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5-Benzofurancarboxylic acid, 3-[2-(acetylamino)ethyl]-, methyl ester (9CI)
MF **C14 H15 N O4**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-[7-(methylsulfinyl)-1-naphthalenyl]ethyl]- (9CI)
MF **C15 H17 N O2 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[8-[2-(acetylamino)ethyl]-5,6,7,8-tetrahydro-2-naphthalenyl]- (9CI)

MF **C16 H22 N2 O2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[3-[1,2,3,4-tetrahydro-7-(1-propenylthio)-1-naphthalenyl]propyl]- (9CI)
MF **C18 H25 N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1-Naphthaleneacetamide, N-(cyclopropylmethyl)-7-[(diethylamino)carbonyl]- (9CI)
MF **C21 H26 N2 O2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN

IN Acetamide, N-[[6-(4-morpholinyl)-2-phenyl-2H-1-benzopyran-3-yl]methyl]- (9CI)
MF **C22 H24 N2 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, N-[2-[5-[(methylamino)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]ethyl]- (9CI)
MF **C17 H18 N4 O3 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, N-[2-(5-bromobenzo[b]thien-3-yl)ethyl]- (9CI)
MF **C17 H14 Br N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Carbamic acid, [8-[2-(acetylamino)ethyl]-6-phenyl-2-naphthalenyl]-, methyl ester (9CI)
MF **C22 H22 N2 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3-Butenamide, N-[2-(5-chlorobenzo[b]thien-3-yl)ethyl]- (9CI)
MF **C14 H14 Cl N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5-Benzofurancarboxylic acid, 3-[2-(acetylamino)ethyl]- (9CI)
MF **C13 H13 N O4**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5-Benzofurancarboxylic acid, 3-[2-[(2-furanylcarbonyl)amino]ethyl]-, methyl ester (9CI)
MF **C17 H15 N O5**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-[7-(methylsulfonyl)-1-naphthalenyl]ethyl]- (9CI)
MF **C15 H17 N O3 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5-Benzofurancarboxylic acid, 3-[2-(benzoylamino)ethyl]-, methyl ester (9CI)
MF **C19 H17 N O4**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[[2-phenyl-6-[(phenylmethyl)thio]-2H-1-benzopyran-3-yl]methyl]- (9CI)
MF **C25 H23 N O2 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2-Naphthalenecarboxamide, 8-[2-[methyl[(propylamino)carbonyl]amino]ethyl]-N-propyl- (9CI)
MF **C21 H29 N3 O2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Cyclohexanecarboxamide, N-[2-[3-(phenylmethyl)-3H-benz[e]indol-9-yl]propyl]- (9CI)
MF **C29 H32 N2 O**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2-Furancarboxamide, N-[2-[5-[(methylamino)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]ethyl]- (9CI)
MF **C15 H16 N4 O4 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzeneacetamide, N-[2-(5-bromobenzo[b]thien-3-yl)ethyl]-3,4-dichloro- (9CI)
MF **C18 H14 Br Cl2 N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Carbamic acid, [8-[2-(acetylamino)ethyl]-5,6,7,8-tetrahydro-2-naphthalenyl]-, hexyl ester (9CI)
MF **C21 H32 N2 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3-Butenamide, N-[2-(5-bromo-2-phenylbenzo[b]thien-3-yl)ethyl]- (9CI)
MF **C20 H18 Br N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5-Benzofurancarbonyl azide, 3-[2-(acetylamino)ethyl]- (9CI)
MF **C13 H12 N4 O3**



L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5-Benzofurancarboxylic acid, 3-[2-[(cyclopentylcarbonyl)amino]ethyl]-, methyl ester (9CI)

MF **C18 H21 N O4**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-[1,2,3,4-tetrahydro-7-(methylsulfinyl)-1-naphthalenyl]ethyl]- (9CI)
MF **C15 H21 N O2 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5-Benzofurancarboxylic acid, 3-[2-[(2-methyl-1-oxopropyl)amino]ethyl]-, methyl ester (9CI)
MF **C16 H19 N O4**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-[5-(2-pyridinylthio)-3-benzofuranyl]ethyl]- (9CI)
MF **C17 H16 N2 O2 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2-Naphthalenecarboxamide, N-(phenylmethyl)-1-[2-[(trifluoroacetyl)amino]ethyl]- (9CI)
MF **C22 H19 F3 N2 O2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3H-Benz[e]indole-2-carboxylic acid, 1-methyl-9-[2-[(phenylacetyl)amino]ethyl]-, ethyl ester (9CI)
MF **C26 H26 N2 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Carbamic acid, [3-[2-(acetylamino)ethyl]-5-benzofuranyl]-, methyl ester (9CI)
MF **C14 H16 N2 O4**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3-Butenamide, N-[2-(5-bromobenzo[b]thien-3-yl)ethyl]- (9CI)
MF **C14 H14 Br N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Carbamic acid, [8-[2-(acetylamino)ethyl]-2-naphthalenyl]-, methyl ester (9CI)
MF **C16 H18 N2 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3H-Naphtho[2,1-b]thiopyran-3-carboxylic acid, 10-[3-[(cyclohexylcarbonyl)amino]propyl]-1-methyl-, ethyl ester (9CI)
MF **C27 H33 N O3 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-[7-[(phenylmethyl)thio]-1-naphthalenyl]ethyl]- (9CI)
MF **C21 H21 N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5-Benzofurancarboxylic acid, 3-[2-[(cyclopropylcarbonyl)amino]ethyl]-, methyl ester (9CI)
MF **C16 H17 N O4**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-[1,2,3,4-tetrahydro-7-(methylsulfonyl)-1-naphthalenyl]ethyl]- (9CI)
MF **C15 H21 N O3 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5-Benzofurancarboxamide, 3-[3-(acetylamino)propyl]-N,N-diphenyl- (9CI)
MF **C26 H24 N2 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[[5-(3-butenylthio)-2-(phenylmethyl)benzo[b]thien-3-yl]methyl]- (9CI)
MF **C22 H23 N O S2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2-Furancarboxamide, N-[2-[7-[(methylamino)carbonyl]-1-naphthalenyl]ethyl]- (9CI)
MF **C19 H18 N2 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzeneacetamide, N-[2-(1,2,3,4-tetrahydro-4-methylbenzo[f]quinolin-10-yl)ethyl]- (9CI)
MF **C24 H26 N2 O**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Carbamic acid, [3-[2-(acetylamino)ethyl]-5-benzofuranyl]methyl-, 1,1-dimethylethyl ester (9CI)
MF **C18 H24 N2 O4**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-(7-fluoro-1,2,3,4-tetrahydro-1-naphthalenyl)ethyl]- (9CI)

MF **C14 H18 F N O**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2-Naphthalenecarboxamide, 8-[2-[(cyclohexylcarbonyl)amino]ethyl]-N-ethynyl- (9CI)
MF **C22 H24 N2 O2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetonitrile, (7-fluoro-3,4-dihydro-1(2H)-naphthalenylidene)- (9CI)
MF **C12 H10 F N**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2-Naphthalenesulfonyl chloride, 8-[2-(acetylamino)ethyl]- (9CI)
MF **C14 H14 Cl N O3 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5-Benzofurancarboxylic acid, 3-[2-[(1-oxo-2-butenyl)amino]ethyl]-, methyl ester (9CI)
MF **C16 H17 N O4**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-[7-[(phenylmethyl)sulfinyl]-1-naphthalenyl]ethyl]- (9CI)
MF **C21 H21 N O2 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5-Benzofurancarboxamide, 3-[2-(benzoylamino)ethyl]-N-methyl- (9CI)
MF **C19 H18 N2 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):50

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Cyclopropanecarboxamide, N-[2-[2-(phenylmethyl)-5-(2-propenylthio)-3-benzofuranyl]ethyl]- (9CI)
MF **C24 H25 N O2 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2-Furancarboxamide, N-[2-[7-[(methylamino)sulfonyl]-1-naphthalenyl]ethyl]- (9CI)
MF **C18 H18 N2 O4 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzeneacetamide, N-[2-(1,2,3,4-tetrahydro-1-hydroxy-4-methylbenzo[f]quinolin-10-yl)ethyl]- (9CI)

MF **C24 H26 N2 O2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Carbamic acid, [3-[2-(benzoylamino)ethyl]-5-benzofuranyl]-, methyl ester (9CI)
MF **C19 H18 N2 O4**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1-Naphthalenamine, N-ethyl-7-fluoro-1,2,3,4-tetrahydro-, hydrochloride (9CI)
MF **C12 H16 F N . Cl H**



● HCl

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Glycine, N-[[3,4-dihydro-4-[2-[(phenylacetyl)amino]ethyl]-2H-1-benzopyran-6-yl]carbonyl]-, ethyl ester (9CI)
MF **C24 H28 N2 O5**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[3-(2,3,7,8,9,10-hexahydro-1-oxo-1H-naphtho[2,1-b]thiopyran-10-yl)propyl]- (9CI)
MF **C18 H23 N O2 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Glycine, N-[[3,4-dihydro-4-[2-[(phenylacetyl)amino]ethyl]-2H-1-benzopyran-6-yl]carbonyl]- (9CI)
MF **C22 H24 N2 O5**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5-Benzofurancarboxamide, 3-[2-(acetylamino)ethyl]- (9CI)
MF **C13 H14 N2 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-[7-[(phenylmethyl)sulfonyl]-1-naphthalenyl]ethyl]- (9CI)
MF **C21 H21 N O3 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5-Benzofurancarboxamide, 3-[2-[(cyclopropylcarbonyl)amino]ethyl]-N-ethyl-
(9CI)
MF **C17 H20 N2 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-[2-phenyl-5-(propylthio)benzo[b]thien-3-yl]ethyl]- (9CI)
MF **C21 H23 N O S2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, N-[2-[7-[(ethylamino)sulfonyl]-1-naphthalenyl]ethyl]- (9CI)
MF **C21 H22 N2 O3 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[[6-ethyl-6,7-dihydro-2-(phenylmethyl)thieno[3,2-f]quinolin-1-yl]methyl]- (9CI)
MF **C23 H24 N2 O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Carbamic acid, [3-[2-[(2-methyl-1-oxopropyl)amino]ethyl]-5-benzofuranyl]-, methyl ester (9CI)
MF **C16 H20 N2 O4**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzeneacetamide, N-[2-(5-bromobenzo[b]thien-3-yl)ethyl]- (9CI)
MF **C18 H16 Br N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzeneacetamide, N-[2-(1,2,3,4-tetrahydro-1,3-dioxobenzo[f]quinolin-5-yl)ethyl]- (9CI)
MF **C23 H20 N2 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-(5-chlorobenzo[b]thien-3-yl)ethyl]- (8CI, 9CI)
MF **C12 H12 Cl N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetyl chloride, [[[3,4-dihydro-4-[2-[(phenylacetyl)amino]ethyl]-2H-1-benzopyran-6-yl]carbonyl]amino]- (9CI)
MF **C22 H23 Cl N2 O4**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5-Benzofurancarboxamide, 3-[2-[(cyclopropylcarbonyl)amino]ethyl]- (9CI)
MF **C15 H16 N2 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, N-[2-(7-mercapto-1-naphthalenyl)ethyl]- (9CI)
MF **C19 H17 N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5-Benzofurancarboxamide, 3-[2-(benzoylamino)ethyl]-N-ethyl- (9CI)
MF **C20 H20 N2 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2-Propenamide, N-[2-[5-[(3-methylbutyl)thio]benzo[b]thien-3-yl]ethyl]-
(9CI)
MF **C18 H23 N O S2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Cyclopropanecarboxamide, N-[2-[7-[(methylamino)sulfonyl]-1-naphthalenyl]ethyl]- (9CI)
MF **C17 H20 N2 O3 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1-Naphthalenamine, N-ethyl-7-(methylthio)-, hydrochloride (9CI)
MF **C13 H15 N S . Cl H**



● HCl

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Carbamic acid, [3-[2-[(2-furanylcarbonyl)amino]ethyl]-5-benzofuranyl]-, methyl ester (9CI)

MF **C17 H16 N2 O5**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, N-[2-(5-bromobenzo[b]thien-3-yl)ethyl]-3,4-dichloro- (9CI)
MF **C17 H12 Br Cl2 N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzo[f]quinoline-5-butanamide, N-cyclohexyl-1,2,3,4-tetrahydro-1,3-dioxo- (9CI)
MF **C23 H26 N2 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzo[b]thiophene, 5-chloro-3-methyl-2-phenyl- (9CI)
MF **C15 H11 Cl S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetonitrile, (3,4-dihydro-7-nitro-1(2H)-naphthalenylidene)- (9CI)
MF **C12 H10 N2 O2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5-Benzofurancarboxamide, 3-[2-[(2-furanylcarbonyl)amino]ethyl]- (9CI)
MF **C16 H14 N2 O4**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Cyclohexanecarboxamide, N-[2-[7-mercapto-3-(phenylmethyl)-1-naphthalenyl]ethyl]- (9CI)
MF **C26 H29 N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 3-[2-(acetylamino)ethyl]-N-methyl- (9CI)
MF **C13 H16 N4 O2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[[2-(2-furanylmethyl)-5-(2-propynylthio)-3-benzofuranyl]methyl]- (9CI)
MF **C19 H17 N O3 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[3-[5-[(methylamino)sulfonyl]-3-benzofuranyl]propyl]- (9CI)
MF **C14 H18 N2 O4 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetonitrile, [3,4-dihydro-7-(methylthio)-1(2H)-naphthalenylidene]- (9CI)
MF **C13 H13 N S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Carbamic acid, [3-[2-[(cyclopentylcarbonyl)amino]ethyl]-5-benzofuranyl]-, methyl ester (9CI)
MF **C18 H22 N2 O4**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2-Furancarboxamide, N-[2-(5-bromobenzo[b]thien-3-yl)ethyl]- (9CI)
MF **C15 H12 Br N O2 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1-Naphthaleneacetamide, N-(cyclopropylmethyl)-7-hydroxy- (9CI)
MF **C16 H17 N O2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzo[b]thiophene, 3-(bromomethyl)-5-chloro-2-phenyl- (9CI)
MF **C15 H10 Br Cl S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Butanamide, N-[2-[7-(methylthio)-1-naphthalenyl]ethyl]- (9CI)
MF **C17 H21 N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5-Benzofurancarboxamide, 3-[2-[(cyclopropylcarbonyl)amino]ethyl]-N-methyl- (9CI)
MF **C16 H18 N2 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-[5-mercapto-2-(phenylmethyl)-3-benzofuranyl]ethyl]- (9CI)
MF **C19 H19 N O2 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzo[b]thiophene-5-carboxamide, 3-[(acetylamino)methyl]-N-(1-methylethyl)-2-(phenylmethyl)-N-2-propynyl- (9CI)
MF **C25 H26 N2 O2 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-[7-methyl-6-phenyl-3-(propylthio)-7H-pyrrolo[2,3-b]pyridin-5-yl]ethyl]- (9CI)
MF **C21 H25 N3 O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-[5-[(propylamino)sulfonyl]-3-benzofuranyl]ethyl]- (9CI)
MF **C15 H20 N2 O4 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-(5-chloro-2-phenylbenzo[b]thien-3-yl)ethyl]- (9CI)
MF **C18 H16 Cl N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Carbamic acid, [5-[(acetylamino)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl]-, methyl ester (9CI)
MF **C13 H16 N2 O5**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2-Butynamide, N-[2-(5-chlorobenzo[b]thien-3-yl)ethyl]- (9CI)
MF **C14 H12 Cl N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzeneacetamide, N-[2-(7-bromo-1-naphthalenyl)ethyl]- (9CI)
MF **C20 H18 Br N O**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):50

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzo[b]thiophene-3-ethanamine, 5-chloro-2-phenyl-, hydrochloride (9CI)
MF **C16 H14 Cl N S . Cl H**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Cyclopropanecarboxamide, N-[2-[7-(methylthio)-1-naphthalenyl]ethyl]- (9CI)
MF **C17 H19 N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5-Benzofurancarboxamide, 3-[2-(acetylamino)ethyl]-N-methyl- (9CI)
MF **C14 H16 N2 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Cyclopropanecarboxamide, N-[2-[5-mercapto-2-(phenylmethyl)-3-benzofuranyl]ethyl]- (9CI)
MF **C21 H21 N O2 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5-Benzofurancarboxamide, 3-[2-(benzoylamino)ethyl]- (9CI)
MF **C18 H16 N2 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Propanamide, N-[4-(butylthio)-2,3-dihydro-1H-phenalen-2-yl]- (9CI)
MF **C20 H25 N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzamide, N-[2-[5-[(cyclopropylamino)sulfonyl]-3-benzofuranyl]ethyl]-
(9CI)
MF **C20 H20 N2 O4 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2-Propenamide, N-[2-(5-chlorobenzo[b]thien-3-yl)ethyl]- (9CI)
MF **C13 H12 Cl N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Carbamic acid, [3-[(acetylamino)methyl]-3,4-dihydro-2H-1-benzopyran-6-yl]-, methyl ester (9CI)
MF **C14 H18 N2 O4**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Butanamide, 4-chloro-N-[2-(5-chlorobenzo[b]thien-3-yl)ethyl]- (9CI)
MF **C14 H15 Cl2 N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzeneacetamide, N-[2-(7-iodo-1-naphthalenyl)ethyl]- (9CI)
MF **C20 H18 I N O**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzo[b]thiophene-3-acetonitrile, 5-chloro-2-phenyl- (9CI)
MF **C16 H10 Cl N S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, 2,2,2-trifluoro-N-[2-[7-(methylthio)-1-naphthalenyl]ethyl]- (9CI)
MF **C15 H14 F3 N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5-Benzofurancarboxamide, 3-[2-[(cyclopentylcarbonyl)amino]ethyl]-N-methyl- (9CI)
MF **C18 H22 N2 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzeneacetamide, N-[2-[7-(2-propenylthio)-1-naphthalenyl]ethyl]- (9CI)
MF **C23 H23 N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Cyclopropanecarboxamide, N-[2-[5-(acetylamino)-3-benzofuranyl]ethyl]- (9CI)
MF **C16 H18 N2 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, 2-bromo-N-[2-(3H-naphtho[2,1-b]thiopyran-10-yl)ethyl]- (9CI)
MF **C17 H16 Br N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2-Furancarboxamide, N-[2-[5-[(methylamino)sulfonyl]-3-benzofuranyl]ethyl]- (9CI)
MF **C16 H16 N2 O5 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-(5-chlorobenzo[b]thien-3-yl)ethyl]-2,2,2-trifluoro- (9CI)
MF **C12 H9 Cl F3 N O S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Carbamic acid, [3-[2-(acetylamino)ethyl]-2,3-dihydro-1H-inden-5-yl]-, ethyl ester (9CI)
MF **C16 H22 N2 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2-Furancarboxamide, N-[2-(5-chlorobenzo[b]thien-3-yl)ethyl]- (9CI)
MF **C15 H12 Cl N O2 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzeneacetamide, N-[2-(7-ethenyl-1-naphthalenyl)ethyl]- (9CI)
MF **C22 H21 N O**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L48 174 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetamide, N-[2-(7-methoxy-1-naphthalenyl)ethyl]- (9CI)
MF **C15 H17 N O2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=>